0     

Anandan C, Jankovic J. Botulinum toxin treatment in parkinsonism. J Neurol Sci. 2024;456:122810. PMID: 38056063.

0     

Baizabal-Carvallo JF, Cavanna AE, Jankovic J. Tics emergencies and malignant tourette syndrome: Assessment and management. Neurosci Biobehav Rev. 2024;159:105609. PMID: 38447821.

0     

Comella CL, Jankovic J, Hauser RA, Patel AT, Banach MD, Ehler E, et al. Efficacy and safety of daxibotulinumtoxinA for injection in cervical dystonia: ASPEN-1 phase 3 randomized controlled trial. Neurology. 2024;102(4):e208091. PMID: 38295339.

0     

Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M, et al. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance. Clin Park Relat Disord. 2024;10:100239. PMID: 38419617.

0     

Jankovic J. Is dystonia an immunologic disorder? Parkinsonism Relat Disord. 2024;:106084. PMID: 38462402.

0     

Junker J, Hall J, Berman BD, Vidailhet M, Roze E, Baumer T, et al. Longitudinal predictors of health-related quality of life in isolated dystonia. J Neurol. 2024;271(2):852-63. PMID: 37839041.

0     

McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23(1):37-45. PMID: 38101901.

0     

Rodriguez-Porcel F, Sarva H, Joutsa J, Falup-Pecurariu C, Shukla AW, Mehanna R, et al. Current opinions and practices in post-stroke movement disorders: Survey of Movement Disorders Society members. J Neurol Sci. 2024;458:122925. PMID: 38340409.

0     

Terravecchia C, Mostile G, Chisari CG, Rascuna C, Terranova R, Cicero CE, et al. Retinal thickness in essential tremor and early Parkinson disease: Exploring diagnostic insights. J Neuroophthalmol. 2024;44(1):35-40. PMID: 37523235.

0     

Terravecchia C, Mostile G, Chisari CG, Rascuna C, Terranova R, Cicero CE, et al. Retinal thickness in essential tremor and early Parkinson disease: Exploring diagnostic insights: Response. J Neuroophthalmol. 2024;:. PMID: 38466367.

0     

Vanegas-Arroyave N, Caroff SN, Citrome L, Crasta J, McIntyre RS, Meyer JM, et al. An evidence-based update on anticholinergic use for drug-induced movement disorders. CNS Drugs. 2024;:. PMID: 38502289.

0     

Yuan L, Chen X, Jankovic J, Deng H. CADASIL: A NOTCH3-associated cerebral small vessel disease. J Adv Res. 2024;:. PMID: 38176524.

0     

Albanese A, Bhatia KP, Cardoso F, Comella C, Defazio G, Fung VSC, et al. Isolated cervical dystonia: Diagnosis and classification. Mov Disord. 2023;38(8):1367-78. PMID: 36989390.

0     

Baizabal-Carvallo JF, Alonso-Juarez M, Jankovic J. Contrasting features between Tourette syndrome and secondary tic disorders. J Neural Transm (Vienna). 2023;:1-6. PMID: 37117738.

0     

Baizabal-Carvallo JF, Alonso-Juarez M, Jankovic J. Oromandibular tics associated with Tourette syndrome. J Neurol. 2023;270(5):2591-6. PMID: 36723683.

0     

Baizabal-Carvallo JF, Jankovic J. Secondary dystonia following parenchymal brain tumors. J Neurol Sci. 2023;446:120577. PMID: 36738494.

0     

Baizabal-Carvallo JF, Jankovic J. The clinical characterization of blocking tics in patients with Tourette syndrome. J Mov Disord. 2023;16(2):163-7. PMID: 36872859.

0     

Borders JC, Sevitz JS, Curtis JA, Vanegas-Arroyave N, Troche MS. Quantifying impairments in swallowing safety and efficiency in progressive supranuclear palsy and Parkinson's disease. Dysphagia. 2023;38(5):1342-52. PMID: 36763187.

0     

Branco LRF, Viswanathan A, Tarakad A, Ince NF. Construction of semi-supervised spatial projections to identify the source of beta- and high frequency oscillations in Parkinson's disease. Int IEEE EMBS Conf Neural Eng. 2023;2023:. PMID: 37601420.

0     

Cotton AC, Scorr L, McDonald W, Comella C, Perlmutter JS, Goetz CG, et al. Assessing the severity of cervical dystonia: Ask the doctor or ask the patient? Mov Disord Clin Pract. 2023;10(9):1399-403. PMID: 37772296.

0     

Deng X, Yuan L, Jankovic J, Deng H. The role of the PLA2G6 gene in neurodegenerative diseases. Ageing Res Rev. 2023;89:101957. PMID: 37236368.

0     

Duffley G, Szabo A, Lutz BJ, Mahoney-Rafferty EC, Hess CW, Ramirez-Zamora A, et al. Interactive mobile application for Parkinson's disease deep brain stimulation (MAP DBS): An open-label, multicenter, randomized, controlled clinical trial. Parkinsonism Relat Disord. 2023;109:105346. PMID: 36966051.

0     

Gadot R, Vanegas Arroyave N, Dang H, Anand A, Najera RA, Taneff LY, et al. Association of clinical outcomes and connectivity in awake versus asleep deep brain stimulation for Parkinson disease. J Neurosurg. 2023;138(4):1016-27. PMID: 35932263.

0     

Hull M, Parnes M, Jankovic J. Botulinum neurotoxin injections in children with self-injurious behaviors. Toxins (Basel). 2023;15(4):236. PMID: 37104174.

0     

Jankovic J, Carruthers J, Naumann M, Ogilvie P, Boodhoo T, Attar M, et al. Neutralizing antibody formation with onabotulinumtoxinA (BOTOX((R))) treatment from global registration studies across multiple indications: A meta-analysis. Toxins (Basel). 2023;15(5):. PMID: 37235376.

0     

Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, et al. Safety and efficacy of long-term deutetrabenazine use in children and adolescents with tics associated with Tourette syndrome: An open-label extension study. Mov Disord Clin Pract. 2023;10(9):1388-98. PMID: 37772282.

0     

Jankovic J, Tsui J, Brin MF. Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023;102(S1):e32403. PMID: 37499081.

0     

Lenka A, Jankovic J. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease? Expert Rev Neurother. 2023;23(2):107-22. PMID: 36803618.

0     

Lenka A, Jankovic J. Peripherally-induced movement disorders: An update. Tremor Other Hyperkinet Mov (N Y). 2023;13:8. PMID: 37008994.

0     

Li T, Le W, Jankovic J. Linking the cerebellum to Parkinson disease: An update. Nat Rev Neurol. 2023;19(11):645-54. PMID: 37752351.

0     

Makhoul K, Jankovic J. Driving impairment in movement disorders. Mov Disord Clin Pract. 2023;10(3):369-81. PMID: 36949799.

0     

Makhoul K, Jankovic J. Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol. 2023;270(9):4518-22. PMID: 37301806.

0     

Ozturk M, Hernandez-Pavon JC, Kent A, Pons JL, Telkes I, Tarakad A. Editorial: Peripheral stimulation: Neuromodulation of the central nervous system through existing pathways. Front Neurosci. 2023;17:1285474. PMID: 37886677.

0     

Schneider SA, Desai S, Phokaewvarangkul O, Rosca EC, Sringean J, Anand P, et al. COVID19-associated new-onset movement disorders: A follow-up study. J Neurol. 2023;:1-7. PMID: 36943516.

0     

Troche MS, Curtis JA, Sevitz JS, Dakin AE, Perry SE, Borders JC, et al. Rehabilitating cough dysfunction in Parkinson's disease: A randomized controlled trial. Mov Disord. 2023;38(2):201-11. PMID: 36345090.

0     

Vanegas-Arroyave N, Jankovic J. Spinal cord stimulation for gait disturbances in Parkinson's disease. Expert Rev Neurother. 2023;23(7):651-9. PMID: 37345383.

0     

Vollstedt EJ, Madoev H, Aasly A, Ahmad-Annuar A, Al-Mubarak B, Alcalay RN, et al. Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson's Disease Project. PLoS One. 2023;18(10):e0292180. PMID: 37788254.

0     

Vollstedt EJ, Schaake S, Lohmann K, Padmanabhan S, Brice A, Lesage S, et al. Embracing monogenic Parkinson's disease: The MJFF global genetic PD cohort. Mov Disord. 2023;38(2):286-303. PMID: 36692014.

0     

Baizabal-Carvallo JF, Alonso-Juarez M, Jankovic J. Dystonic motor and phonic tics in Tourette syndrome. J Neurol. 2022;269(10):5312-8. PMID: 35567613.

0     

Baizabal-Carvallo JF, Alonso-Juarez M, Jankovic J. Self-injurious behavior in Tourette syndrome. J Neurol. 2022;269(5):2453-9. PMID: 34596744.

0     

Baizabal-Carvallo JF, Jankovic J. Sex differences in patients with Tourette syndrome. CNS Spectr. 2022;:1-7. PMID: 35170423.

0     

Baizabal-Carvallo JF, Jankovic J. The clinical phenomenology and correlations of oculogyric tics. Acta Neurol Belg. 2022;122(4):925-30. PMID: 35397742.

0     

Bellows S, Jankovic J. Parkinsonism and tremor syndromes. J Neurol Sci. 2022;433:120018. PMID: 34686357.

0     

Bologna M, Truong D, Jankovic J. The etiopathogenetic and pathophysiological spectrum of parkinsonism. J Neurol Sci. 2022;433:120012. PMID: 34642022.

0     

Borders JC, Curtis JA, Sevitz JS, Vanegas-Arroyave N, Troche MS. Immediate effects of sensorimotor training in airway protection (smTAP) on cough outcomes in progressive supranuclear palsy: A feasibility study. Dysphagia. 2022;37(1):74-83. PMID: 33515312.

0     

Clark LN, Gao Y, Wang GT, Hernandez N, Ashley-Koch A, Jankovic J, et al. Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiology. EBioMedicine. 2022;85:104290. PMID: 36183486.

0     

Defazio G, Gigante AF, Hallett M, Berardelli A, Perlmutter JS, Berman BD, et al. Motor and psychiatric features in idiopathic blepharospasm: A data-driven cluster analysis. Parkinsonism Relat Disord. 2022;104:94-8. PMID: 36306537.

0     

Defazio G, Hallett M, Berardelli A, Perlmutter JS, Berman BD, Jankovic J, et al. Measurement properties of clinical scales rating the severity of blepharospasm: A multicenter observational study. Mov Disord Clin Pract. 2022;9(7):949-55. PMID: 36247913.

0     

Du W, Bain PG, Defazio G, Jankovic J, Kim CY, Tan EK, et al. The conundrum of dystonia in essential tremor patients: How does one classify these cases? Tremor Other Hyperkinet Mov (N Y). 2022;12:15. PMID: 35646424.

0     

Hill EJ, Robak LA, Al-Ouran R, Deger J, Fong JC, Vandeventer PJ, et al. Genome sequencing in the Parkinson disease clinic. Neurol Genet. 2022;8(4):e200002. PMID: 35747619.

0     

Jankovic J, Truong DD, Bologna M. Editorial "Parkinsonism across the spectrum of movement disorders and beyond". J Neurol Sci. 2022;433:120013. PMID: 34625287.

0     

Kilic-Berkmen G, Pirio Richardson S, Perlmutter JS, Hallett M, Klein C, Wagle-Shukla A, et al. Current guidelines for classifying and diagnosing cervical dystonia: Empirical evidence and recommendations. Mov Disord Clin Pract. 2022;9(2):183-90. PMID: 35146058.

0     

Lenka A, Di Maria G, Lamotte G, Bahroo L, Jankovic J. Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease. Expert Rev Neurother. 2022;22(6):489-98. PMID: 35710101.

0     

Lenka A, King C, Soni M, Hu N, Motamedi GK. Tacrolimus-induced generalized tremor with excellent response to primidone. Ann Mov Disord. 2022;5(1):74-6. DOI: 10.4103/AOMD.AOMD_30_21.

0     

Lenka A, Pandey S. Essential tremor: Five new things. Neurol Clin Pract. 2022;12(2):183-6. PMID: 35747894.

0     

Lenka A, Prashanth LK. Dystonia gravidarum: The twists and turns during pregnancy. Ann Mov Disord. 2022;5(1):71-3. DOI: 10.4103/AOMD.AOMD_29_21.

0     

Liao C, Castonguay CE, Heilbron K, Vuokila V, Medeiros M, Houle G, et al. Association of essential tremor with novel risk loci: A genome-wide association study and meta-analysis. JAMA Neurol. 2022;79(2):185-93. PMID: 34982113.

0     

Lu S, Ma M, Mao X, Bacino CA, Jankovic J, Sutton VR, et al. De novo variants in FRMD5 are associated with developmental delay, intellectual disability, ataxia, and abnormalities of eye movement. Am J Hum Genet. 2022;109(10):1932-1943. PMID: 36206744.

0     

Mailankody P, Battu R, Lenka A, Mohammed Shereef PM, Thennarasu K, Yadav R, et al. Retinal changes in Parkinson's disease: A longitudinal follow-up study. Neurol India. 2022;70:1149-53. DOI: 10.4103/0028-3886.349658.

0     

Scorr LM, Cho HJ, Kilic-Berkmen G, McKay JL, Hallett M, Klein C, et al. Clinical features and evolution of blepharospasm: A multicenter international cohort and systematic literature review. Dystonia. 2022;1:. PMID: 36248010.

0     

Shah C, Jackson GR, Sarwar AI, Mandava P, Jamal F. Treatment patterns in essential tremor: A retrospective analysis. Tremor Other Hyperkinet Mov (N Y). 2022;12:10. PMID: 35415009.

0     

Vijayakumar D, Jankovic J. Slowing Parkinson's disease progression with vaccination and other immunotherapies. CNS Drugs. 2022;36(4):327-43. PMID: 35212935.

0     

Vu JP, Cisneros E, Lee HY, Le L, Chen Q, Guo XA, et al. Head tremor in cervical dystonia: Quantifying severity with computer vision. J Neurol Sci. 2022;434:120154. PMID: 35101766.

0     

Zhang Z, Cisneros E, Lee HY, Vu JP, Chen Q, Benadof CN, et al. Hold that pose: Capturing cervical dystonia's head deviation severity from video. Ann Clin Transl Neurol. 2022;9(5):684-94. PMID: 35333449.

0     

Zhou ZD, Jankovic J, Ashizawa T, Tan EK. Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions. Nat Rev Neurol. 2022;18(3):145-57. PMID: 35022573.

0     

Alfradique-Dunham I, Al-Ouran R, von Coelln R, Blauwendraat C, Hill E, Luo L, et al. Genome-wide association study meta-analysis for Parkinson disease motor subtypes. Neurol Genet. 2021;7(2):e557. PMID: 33987465.

0     

Anandan C, Jankovic J. Botulinum toxin in movement disorders: An update. Toxins (Basel). 2021;13(1):. PMID: 33430071.

0     

Baizabal-Carvallo JF, Jankovic J. Beyond tics: movement disorders in patients with Tourette syndrome. J Neural Transm (Vienna). 2021;128(8):1177-83. PMID: 34302221.

0     

Bellows ST, Jankovic J. Phenotypic features of isolated essential tremor, essential tremor plus, and essential tremor-Parkinson's disease in a movement disorders clinic. Tremor Other Hyperkinet Mov (N Y). 2021;11:12. PMID: 33828900.

0     

Billnitzer A, Jankovic J. Pilot study to evaluate pimavanserin for the treatment of motor and behavioral symptoms of Tourette syndrome. Mov Disord Clin Pract. 2021;8(5):694-700. PMID: 34307741.

0     

Billnitzer A, Jankovic J. The clinical value of patient home videos in movement disorders. Tremor Other Hyperkinet Mov (N Y). 2021;11:37. PMID: 34692230.

0     

Cisneros E, Vu JP, Lee HY, Chen Q, Benadof CN, Zhang Z, et al. Does raising the arms modify head tremor severity in cervical dystonia? Tremor Other Hyperkinet Mov (N Y). 2021;11:21. PMID: 34221696.

0     

Coffey B, Jankovic J, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, et al. Efficacy and safety of fixed-dose deutetrabenazine in children and adolescents for tics associated with Tourette syndrome: A randomized clinical trial. JAMA Netw Open. 2021;4(10):e2129397. PMID: 34661664.

0     

Defazio G, Jinnah HA, Berardelli A, Perlmutter JS, Berkmen GK, Berman BD, et al. Diagnostic criteria for blepharospasm: A multicenter international study. Parkinsonism Relat Disord. 2021;91:109-14. PMID: 34583301.

0     

Enver N, Borders JC, Curtis JA, Sevitz JS, Vanegas-Arroyave N, Troche MS. The role of vocal fold bowing on cough and swallowing dysfunction in progressive supranuclear palsy. Laryngoscope. 2021;131(6):1217-22. PMID: 32687232.

0     

Feeney MP, Xu Y, Surface M, Shah H, Vanegas-Arroyave N, Chan AK, et al. The impact of COVID-19 and social distancing on people with Parkinson's disease: A survey study. NPJ Parkinsons Dis. 2021;7(1):10. PMID: 33479241.

0     

Gatto EM, Walker RH, Gonzalez C, Cesarini M, Cossu G, Stephen CD, et al. Worldwide barriers to genetic testing for movement disorders. Eur J Neurol. 2021;28(6):1901-9. PMID: 33730413.

0     

Goldstein DS, Sullivan P, Holmes C, Lamotte G, Lenka A, Sharabi Y. Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies. J Neurochem. 2021;158(2):554-68. PMID: 33894018.

0     

Hafeez MU, Moore M, Hafeez K, Jankovic J. Exploring the role of botulinum toxin in critical care. Expert Rev Neurother. 2021;21(8):881-94. PMID: 34281468.

0     

Hill EJ, Jankovic J. Antiglutamic acid decarboxylase 65 antibody-associated hemiataxia. Neurol Clin Pract. 2021;11(4):e564-6. PMID: 34484960.

0     

Hill EJ, Mangleburg CG, Alfradique-Dunham I, Ripperger B, Stillwell A, Saade H, et al. Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. Parkinsonism Relat Disord. 2021;84:105-11. PMID: 33607526.

0     

Hull M, Parnes M, Jankovic J. Botulinum neurotoxin injections in childhood opisthotonus. Toxins (Basel). 2021;13(2):. PMID: 33673369.

0     

Hull M, Parnes M, Jankovic J. Increased incidence of functional (psychogenic) movement disorders in children and adults amid the COVID-19 pandemic: A cross-sectional study. Neurol Clin Pract. 2021;11(5):e686-e690. PMID: 34840884.

0     

Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, et al. Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette syndrome: A randomized clinical trial. JAMA Netw Open. 2021;4(10):e2128204. PMID: 34609495.

0     

Junker J, Berman BD, Hall J, Wahba DW, Brandt V, Perlmutter JS, et al. Quality of life in isolated dystonia: Non-motor manifestations matter. J Neurol Neurosurg Psychiatry. 2021;:. PMID: 33563813.

0     

Klopstock T, Videnovic A, Bischoff AT, Bonnet C, Cif L, Comella C, et al. Fosmetpantotenate randomized controlled trial in pantothenate kinase-associated neurodegeneration. Mov Disord. 2021;36(6):1342-52. PMID: 33200489.

0     

Lamotte G, Lenka A. Brainstem predominant posterior reversible encephalopathy syndrome. Neurol India. 2021;69(2):536-7. PMID: 33904504.

0     

Lenka A, Hegde S, Arumugham SS, Singh P, Yadav R, Pal PK. Cognitive correlates of visual and minor hallucinations in Parkinson's disease. Can J Neurol Sci. 2021;:1-5. PMID: 34895381.

0     

Lenka A, Jankovic J. Sports-related dystonia. Tremor Other Hyperkinet Mov (N Y). 2021;11:54. PMID: 35036047.

0     

Lenka A, Jankovic J. Tremor syndromes: An updated review. Front Neurol. 2021;12:684835. PMID: 34381412.

0     

Lenka A, Lamotte G, Goldstein DS. Cardiac(18) F-dopamine PET distinguishes PD with orthostatic hypotension from Parkinsonian MSA. Mov Disord Clin Pract. 2021;8(4):582-6. PMID: 33981791.

0     

Lenka A, Louis ED. Primidone intolerance in essential tremor: Is it more than just age? Tremor Other Hyperkinet Mov (N Y). 2021;11:57. PMID: 35070493.

0     

Lenka A, Mittal SO, Lamotte G, Pagan FL. A pragmatic approach to the perioperative management of Parkinson's disease. Can J Neurol Sci. 2021;48(3):299-307. PMID: 32959743.

0     

Litvan I, Proudfoot JA, Martin ER, Standaert D, Riley D, Hall D, et al. Gene-environment interactions in progressive supranuclear palsy. Front Neurol. 2021;12:664796. PMID: 33897612.

0     

Makhoul K, Jankovic J. Parkinson's disease after COVID-19. J Neurol Sci. 2021;422:117331. PMID: 33540185.

0     

Makhoul K, Jankovic J. Tourette syndrome and driving. Mov Disord Clin Pract. 2021;8(5):763-8. PMID: 34307750.

0     

Marsili L, Bologna M, Jankovic J, Colosimo C. Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: A critical reappraisal. Expert Opin Drug Saf. 2021;20(6):695-705. PMID: 33831328.

0     

Mitsikostas DD, Dekundy A, Hanschmann A, Althaus M, Scheschonka A, Pagan F, et al. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naive subjects. Curr Med Res Opin. 2021;37(10):1761-8. PMID: 34384301.

0     

Mostile G, Terranova R, Rascuna C, Terravecchia C, Cicero CE, Giuliano L, et al. Clinical-instrumental patterns of neurodegeneration in essential tremor: A data-driven approach. Parkinsonism Relat Disord. 2021;87:124-9. PMID: 34030068.

0     

Niemann N, Billnitzer A, Jankovic J. Parkinson's disease and skin. Parkinsonism Relat Disord. 2021;82:61-76. PMID: 33248395.

0     

Radmard S, Ortega RA, Ford B, Vanegas-Arroyave N, McKhann GM, Sheth SA, et al. Using computerized spiral analysis to evaluate deep brain stimulation outcomes in Parkinson disease. Clin Neurol Neurosurg. 2021;208:106878. DOI: https://doi.org/10.1016/j.clineuro.2021.106878.

0     

Safai A, Vakharia N, Prasad S, Saini J, Shah A, Lenka A, et al. Multimodal brain connectomics-based prediction of Parkinson's disease using graph attention networks. Front Neurosci. 2021;15:741489. PMID: 35280342.

0     

Scorr LM, Factor SA, Parra SP, Kaye R, Paniello RC, Norris SA, et al. Oromandibular dystonia: A clinical examination of 2,020 cases. Front Neurol. 2021;12:700714. PMID: 34603182.

0     

Shaikh AG, Beylergil SB, Scorr L, Kilic-Berkmen G, Freeman A, Klein C, et al. Dystonia and tremor: A cross-sectional study of the dystonia coalition cohort. Neurology. 2021;96(4):e563-e574. PMID: 33046615.

0     

Sun YV, Li C, Hui Q, Huang Y, Barbano R, Rodriguez R, et al. A multi-center genome-wide association study of cervical dystonia. Mov Disord. 2021;36(12):2795-801. PMID: 34320236.

0     

Triano MJ, Haberstroh WD, Lenka A, Whelton SA. Relapsed granulomatosis with polyangiitis with panhypopituitarism. BMJ Case Rep. 2021;14(1):. PMID: 33509867.

0     

Tsetsos F, Yu D, Sul JH, Huang AY, Illmann C, Osiecki L, et al. Synaptic processes and immune-related pathways implicated in Tourette syndrome. Transl Psychiatry. 2021;11(1):56. PMID: 33462189.

0     

Vu JP, Lee HY, Chen Q, Cisneros E, Barbano RL, Goetz CG, et al. Head tremor and pain in cervical dystonia. J Neurol. 2021;268(5):1945-50. PMID: 33417005.

0     

Wang M, Sajobi T, Morgante F, Adler C, Agarwal P, Baumer T, et al. Predictive modelling of spread in adult-onset isolated dystonia: key properties and effect of tremor inclusion. Eur J Neurol. 2021;28(12):3999-4009. PMID: 34296504.

0     

Wang Q, Akram H, Muthuraman M, Gonzalez-Escamilla G, Sheth SA, Oxenford S, et al. Normative vs. patient-specific brain connectivity in deep brain stimulation. Neuroimage. 2021;224:117307. PMID: 32861787.

0     

Welton T, Cardoso F, Carr JA, Chan LL, Deuschl G, Jankovic J, et al. Essential tremor. Nat Rev Dis Primers. 2021;7(1):83. PMID: 34764294.

0     

Zhang JF, Wang XX, Feng Y, Fekete R, Jankovic J, Wu YC. Impulse control disorders in Parkinson's disease: Epidemiology, pathogenesis and therapeutic strategies. Front Psychiatry. 2021;12:635494. PMID: 33633615.

7

Baizabal-Carvallo JF, Alonso-Juarez M, Jankovic J. Functional gait disorders, clinical phenomenology, and classification. Neurol Sci. 2020;41(4):911-5. PMID: 31832998.

13

Baizabal-Carvallo JF, Jankovic J. Gender differences in functional movement disorders. Mov Disord Clin Pract. 2020;7(2):182-7. PMID: 32071937.

0     

Baizabal-Carvallo JF, Jankovic J. Reply to gender differences in functional movement disorders: Sociocultural or biological? Mov Disord Clin Pract. 2020;7(4):480-1. PMID: 32373674.

0     

Bashir HH, Jankovic J. Treatment of tardive dyskinesia. Neurol Clin. 2020;38(2):379-96. PMID: 32279716.

0     

Bellows S, Jankovic J. Reply to comment on re-visiting immunogenicity associated with botulinum toxin treatment. Toxins 2019, 11, 491. Toxins (Basel). 2020;12(2):. PMID: 31979241.

0     

Bellows S, Jankovic J. Treatment of dystonia and tics. Clin Park Relat Disord. 2020;2:12-9. DOI: https://doi.org/10.1016/j.prdoa.2019.11.005.

0     

Bhattacharya A, Lenka A, Stezin A, Kamble N, Pal PK. Overview of sleep disturbances and their management in Parkinson plus disorders. J Neurol Sci. 2020;415:116891. PMID: 32446010.

0     

Bhidayasiri R, Kane JM, Frei KP, Caroff SN, Correll CU, Fahn S, et al. Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord. 2020;77:141-5. PMID: 32823151.

0     

Billnitzer A, Jankovic J. Current management of tics and Tourette syndrome: Behavioral, pharmacologic, and surgical treatments. Neurotherapeutics. 2020;17(4):1681-93. PMID: 32856174.

52

Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain. 2020;143(1):234-48. PMID: 31755958.

0     

Chaithra SP, Stezin A, Prasad S, Holla VV, Lenka A, Kamble N, et al. A case of late-onset dopa-responsive isolated dystonia secondary to a novel tyrosine hydroxylase gene variant. Clin Park Relat Disord. 2020;3:100039. PMID: 34316625.

0     

Chen Q, Vu JP, Cisneros E, Benadof CN, Zhang Z, Barbano RL, et al. Postural directionality and head tremor in cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2020;10:. PMID: 32015932.

0     

Cisneros E, Stebbins GT, Chen Q, Vu JP, Benadof CN, Zhang Z, et al. It's tricky: Rating alleviating maneuvers in cervical dystonia. J Neurol Sci. 2020;419:117205. PMID: 33160248.

0     

Gupta HV, Lenka A. Tremor in paraneoplastic cerebellar degeneration: Beyond intention tremor. Ann Indian Acad Neurol. 2020;23(3):368-9. PMID: 32606537.

0     

Jankovic J, Coffey B, Claassen DO, Stamler D, Gertz BJ, Garofalo EA, et al. Development of deutetrabenazine as a potential new non-antipsychotic treatment for Tourette syndrome in children and adolescents. CNS Spectr. 2020;25(2):297. PMID: 32331029.

0     

Jankovic J, Okun MS, Kordower JH. Stem cells: Scientific and ethical quandaries of a personalized approach to Parkinson's disease. Mov Disord. 2020;35(8):1312-4. PMID: 32529662.

0     

Jankovic J, Tan EK. Parkinson's disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795-808. PMID: 32576618.

0     

Jankovic J. Treatment of movement disorders. Neurol Clin. 2020;38(2):xiii-xiv. PMID: 32279722.

0     

Jankovic J. Treatment of tics associated with Tourette syndrome. J Neural Transm (Vienna). 2020;127(5):843-50. PMID: 31955299.

0     

Kostick K, Storch EA, Zuk P, Blumenthal-Barby JS, Torgerson L, Yoshor D, et al. Strategies to mitigate impacts of the COVID-19 pandemic on patients treated with deep brain stimulation. Brain Stimul. 2020;13(6):1642-3. PMID: 33017673.

0     

Lamotte G, Holmes C, Sullivan P, Lenka A, Goldstein DS. Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. Ann Clin Transl Neurol. 2020;7(12):2450-60. PMID: 33216462.

0     

Lenka A, Ingalhalikar M, Shah A, Saini J, Arumugham SS, Hegde S, et al. Abnormalities in the white matter tracts in patients with Parkinson disease and psychosis. Neurology. 2020;94(18):e1876-84. PMID: 32317347.

0     

Lenka A, Louis ED. Do we belittle essential tremor by calling it a syndrome rather than a disease? Yes. Front Neurol. 2020;11:522687. PMID: 33178097.

0     

Lenka A, Louis ED. Essential tremor: Is the word "essential" really essential? Parkinsonism Relat Disord. 2020;81:103-5. PMID: 33120070.

0     

Lenka A. Mirtazapine for the treatment of psychosis in Parkinson's disease: Any silver linings? Ann Mov Disord. 2020;3(1):69-70. DOI: 10.4103/AOMD.AOMD_9_20.

0     

Louis ED, Bares M, Benito-Leon J, Fahn S, Frucht SJ, Jankovic J, et al. Essential tremor-plus: A controversial new concept. Lancet Neurol. 2020;19(3):266-70. PMID: 31767343.

0     

Norris SA, Jinnah HA, Klein C, Jankovic J, Berman BD, Roze E, et al. Clinical and demographic characteristics of upper limb dystonia. Mov Disord. 2020;35(11):2086-90. PMID: 32845549.

0     

Ozturk M, Kaku H, Jimenez-Shahed J, Viswanathan A, Sheth SA, Kumar S, et al. Subthalamic single cell and oscillatory neural dynamics of a dyskinetic medicated patient with Parkinson's disease. Front Neurosci. 2020;14:391. PMID: 32390796.

0     

Ozturk M, Telkes I, Jimenez-Shahed J, Viswanathan A, Tarakad A, Kumar S, et al. Randomized, double-blind assessment of LFP versus SUA guidance in STN-DBS lead implantation: A pilot study. Front Neurosci. 2020;14:611. PMID: 32655356.

0     

Pick S, Anderson DG, Asadi-Pooya AA, Aybek S, Baslet G, Bloem BR, et al. Outcome measurement in functional neurological disorder: A systematic review and recommendations. J Neurol Neurosurg Psychiatry. 2020;91(6):638-49. PMID: 32111637.

0     

Rezvanian S, Litvan I, Standaert D, Jankovic J, Reich SG, Hall D, et al. Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord. 2020;78:56-60. PMID: 32731191.

0     

Robak LA, Du R, Yuan B, Gu S, Alfradique-Dunham I, Kondapalli V, et al. Integrated sequencing and array comparative genomic hybridization in familial Parkinson disease. Neurol Genet. 2020;6(5):e498. PMID: 32802956.

0     

Rutherford BR, Choi J, Slifstein M, O'Boyle K, Abi-Dargham A, Brown PJ, et al. Neuroanatomical predictors of L-DOPA response in older adults with psychomotor slowing and depression: A pilot study. J Affect Disord. 2020;265:439-44. PMID: 32090770.

5

Schneider RB, Jimenez-Shahed J, Abraham DS, Thibault DP, Mantri S, Fullard M, et al. Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. Parkinsonism Relat Disord. 2020;70:96-102. PMID: 31866156.

0     

Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J. Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol. 2020;16(6):303-18. PMID: 32332985.

0     

Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, et al. EASE LID 2: A 2-year open-label trial of Gocovri (amantadine) extended release for dyskinesia in Parkinson's disease. J Parkinsons Dis. 2020;10(2):543-58. PMID: 31929122.

0     

Tarakad A. Clinical rating scales and quantitative assessments of movement disorders. Neurol Clin. 2020;38(2):231-54. PMID: 32279708.

0     

Torelli S, Lenka A, Khan F, Amjad F. Clinical reasoning: An 81-year-old woman with confusion, weakness, and left-sided hemineglect. Neurology. 2020;95(22):e3060-4. PMID: 32727841.

0     

York MK, Benge JF, Hunter C, Jankovic J. A validation of a self-administered screening test for Parkinson's disease. J Neurol Sci. 2020;418:117116. PMID: 32919368.

0     

Anandan C, Milone M, Liewluck T. Intramuscular interstitial amyloid deposition does not impact anoctaminopathy-5 phenotype. Muscle Nerve. 2019;59(1):133-7. PMID: 30320887.

46

Baizabal-Carvallo JF, Hallett M, Jankovic J. Pathogenesis and pathophysiology of functional (psychogenic) movement disorders. Neurobiol Dis. 2019;127:32-44. PMID: 30798005.

0     

Baizabal-Carvallo JF, Jankovic J. The wide spectrum of functional movement disorders. JAMA Neurol. 2019;76(2):235-6. PMID: 30535193.

30

Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel). 2019;11(9):. PMID: 31454941.

109

Blauwendraat C, Heilbron K, Vallerga CL, Bandres-Ciga S, von Coelln R, Pihlstrom L, et al. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and alpha-synuclein mechanisms. Mov Disord. 2019;34(6):866-75. PMID: 30957308.

0     

Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci U S A. 2019;116(11):5108-17. PMID: 30796187.

5

Dashtipour K, Mari Z, Jankovic J, Adler CH, Schwartz M, Brin MF. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. J Neurol Sci. 2019;405:116413. PMID: 31494402.

6

Deng H, Wu S, Jankovic J. [Essential tremor: Genetic update]. Expert Rev Mol Med. 2019;21:e8. PMID: 31818346.

17

Gregory A, Lotia M, Jeong SY, Fox R, Zhen D, Sanford L, et al. Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN). Mol Genet Genomic Med. 2019;7(7):e736. PMID: 31087512.

20

Hammoud N, Jimenez-Shahed J. Chronic neurologic effects of alcohol. Clin Liver Dis. 2019;23(1):141-55. PMID: 30454828.

17

Jankovic J. Pathogenesis-targeted therapeutic strategies in Parkinson's disease. Mov Disord. 2019;34(1):41-4. PMID: 30484897.

0     

Jha M, Kamble N, Lenka A, Yadav R, Purushottam M, Jain S, et al. Sleep disturbances in patients with Huntington's disease: A questionnaire-based study. Ann Mov Disord. 2019;2(1):9-14. DOI: 10.4103/AOMD.AOMD_1_19.

0     

Kamble N, Yadav R, Lenka A, Kumar K, Nagaraju BC, Pal PK. Impaired sleep quality and cognition in patients of Parkinson's disease with REM sleep behavior disorder: A comparative study. Sleep Med. 2019;62:1-5. PMID: 31518942.

0     

Lenka A, Gomathinayagam V, Bahroo LB. Approach to the management of psychosis in Parkinson's disease. Ann Mov Disord. 2019;2(3):83-90. DOI: 10.4103/AOMD.AOMD_27_19.

0     

Lenka A, Kamat A, Mittal SO. Spectrum of movement disorders in patients with neuroinvasive West Nile virus infection. Mov Disord Clin Pract. 2019;6(6):426-33. PMID: 31392241.

0     

Lenka A, Louis ED. Revisiting the clinical phenomenology of "cerebellar tremor": Beyond the intention tremor. Cerebellum. 2019;18(3):565-74. PMID: 30565088.

0     

Lenka A, Pagonabarraga J, Pal PK, Bejr-Kasem H, Kulisvesky J. Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications. Neurology. 2019;93(6):259-66. PMID: 31289146.

0     

Mailankody P, Lenka A, Pal PK. The role of optical coherence tomography in parkinsonism: A critical review. J Neurol Sci. 2019;403:67-74. PMID: 31228766.

18

Mehanna R, Jankovic J. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019;65:39-48. PMID: 31176633.

14

Merola A, Dwivedi AK, Shaikh AG, Tareen TK, Da Prat GA, Kauffman MA, et al. Head tremor at disease onset: An ataxic phenotype of cervical dystonia. J Neurol. 2019;266(8):1844-51. PMID: 31028543.

8

Migliore S, Jankovic J, Squitieri F. Genetic counseling in Huntington's disease: Potential new challenges on horizon? Front Neurol. 2019;10:453. PMID: 31114543.

19

Mitchell KT, Larson P, Starr PA, Okun MS, Wharen RE, Jr, et al. Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. Parkinsonism Relat Disord. 2019;60:126-32. PMID: 30220556.

14

Mittal SO, Lenka A, Jankovic J. Botulinum toxin for the treatment of tremor. Parkinsonism Relat Disord. 2019;63:31-41. PMID: 30709779.

0     

Mittal SO, Lenka A, Jankovic J. Cervical dystonia: An update on therapeutics. Expert Opin Orphan Drugs. 2019;7(4):199-209. DOI: 10.1080/21678707.2019.1613978.

6

Mostile G, Barone R, Nicoletti A, Rizzo R, Martinelli D, Sturiale L, et al. Hyperkinetic movement disorders in congenital disorders of glycosylation. Eur J Neurol. 2019;26(9):1226-34. PMID: 31132195.

363

Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-102. PMID: 31701892.

23

Niemann N, Jankovic J. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. 2019;67:74-89. PMID: 31272925.

18

Niemann N, Jankovic J. Real-world experience with VMAT2 inhibitors. Clin Neuropharmacol. 2019;42(2):37-41. PMID: 30870235.

9

Parnes M, Bashir H, Jankovic J. Is benign hereditary chorea really benign? Brain-lung-thyroid syndrome caused by NKX2-1 mutations. Mov Disord Clin Pract. 2019;6(1):34-9. PMID: 30746413.

0     

Prasad S, Bhalsing KS, Jhunjhunwala K, Lenka A, Binu VS, Pal PK. Phenotypic variability of essential tremor based on the age at onset. Can J Neurol Sci. 2019;46(2):192-8. PMID: 30688180.

0     

Pretegiani E, Vanegas-Arroyave N, FitzGibbon EJ, Hallett M, Optican LM. Evidence from Parkinson's disease that the superior colliculus couples action and perception. Mov Disord. 2019;34(11):1680-9. PMID: 31633242.

58

Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, et al. Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):907-15. PMID: 31061209.

85

Pringsheim T, Okun MS, Muller-Vahl K, Martino D, Jankovic J, Cavanna AE, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896-906. PMID: 31061208.

4

Rabadia SV, Litvan I, Juncos J, Bordelon Y, Riley DE, Standaert D, et al. Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord. 2019;66:166-70. PMID: 31420308.

0     

Rutherford BR, Slifstein M, Chen C, Abi-Dargham A, Brown PJ, Wall MW, et al. Effects of L-DOPA monotherapy on psychomotor speed and [(11)c]raclopride binding in high-risk older adults with depression. Biol Psychiatry. 2019;86(3):221-9. PMID: 31178096.

11

Savitt D, Jankovic J. Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. J Neurol Sci. 2019;402:57-61. PMID: 31103960.

1

Savitt D, Jankovic J. Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration. Neurol Clin Pract. 2019;9(1):e7-9. PMID: 30859014.

36

Savitt D, Jankovic J. Targeting alpha-synuclein in Parkinson's disease: Progress towards the development of disease-modifying therapeutics. Drugs. 2019;79(8):797-810. PMID: 30982161.

8

Shoeibi A, Litvan I, Juncos JL, Bordelon Y, Riley D, Standaert D, et al. Are the International Parkinson Disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes? Parkinsonism Relat Disord. 2019;69:34-9. PMID: 31665686.

0     

Singh P, Lenka A, Stezin A, Jhunjhunwala K, Pal PK, Ghosal A, et al. Basal ganglia contributions during the learning of a visuomotor rotation: Effect of dopamine, deep brain stimulation and reinforcement. Eur J Neurosci. 2019;50(8):3349-64. PMID: 31220389.

23

Testa CM, Jankovic J. Huntington disease: A quarter century of progress since the gene discovery. J Neurol Sci. 2019;396:52-68. PMID: 30419368.

2

Weaver J, Sarva H, Barone D, Bobker S, Bushara K, Hiller A, et al. McLeod syndrome: Five new pedigrees with novel mutations. Parkinsonism Relat Disord. 2019;64:293-9. PMID: 31103486.

7

Wijemanne S, Jankovic J. Hand, foot, and spine deformities in parkinsonian disorders. J Neural Transm (Vienna). 2019;126(3):253-64. PMID: 30809710.

47

Yu D, Sul JH, Tsetsos F, Nawaz MS, Huang AY, Zelaya I, et al. Interrogating the genetic determinants of Tourette's syndrome and other tic disorders through genome-wide association studies. Am J Psychiatry. 2019;176(3):217-27. PMID: 30818990.

0     

Albanese A, Cardoso F, Fujinaga Y, Jankovic J, Rummel A, Schiavo G. Toxins 2017 conference in Madrid. Toxicon. 2018;147:1. PMID: 29571683.

0     

Alcalay RN, Wolf P, Levy OA, Kang UJ, Waters C, Fahn S, et al. Alpha galactosidase A activity in Parkinson's disease. Neurobiol Dis. 2018;112:85-90. PMID: 29369793.

0     

Anandan C, Cipriani MA, Laughlin RS, Niu Z, Milone M. Rhabdomyolysis and fluctuating asymptomatic hyperCKemia associated with CACNA1S variant. Eur J Neurol. 2018;25(2):417-9. PMID: 29193480.

0     

Anandan C, Milone M. An adult with a rare form of congenital fiber type disproportion. Muscle Nerve. 2018;57(1):E97-E99. PMID: 28881016.

35

Baizabal-Carvallo JF, Jankovic J. Autoimmune and paraneoplastic movement disorders: An update. J Neurol Sci. 2018;385:175-84. PMID: 29406902.

0     

Balint B, Mencacci NE, Valente EM, Pisani A, Rothwell J, Jankovic J, et al. Author correction: Dystonia. Nat Rev Dis Primers. 2018;4(1):37. PMID: 30341354.

109

Balint B, Mencacci NE, Valente EM, Pisani A, Rothwell J, Jankovic J, et al. Dystonia. Nat Rev Dis Primers. 2018;4(1):25. PMID: 30237473.

4

Bashir H, Jankovic J. Deutetrabenazine for the treatment of Huntington's chorea. Expert Rev Neurother. 2018;18(8):625-31. PMID: 29996061.

22

Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurother. 2018;18(1):51-63. PMID: 29120264.

4

Deng H, Fan K, Jankovic J. The role of TMEM230 gene in Parkinson's disease. J Parkinsons Dis. 2018;8(4):469-77. PMID: 30175983.

216

Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev. 2018;42:72-85. PMID: 29288112.

25

Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci. 2018;389:10-6. PMID: 29433810.

24

Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, et al. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord. 2018;33(8):1272-80. PMID: 30192018.

118

Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease: A randomized clinical trial. JAMA Neurol. 2018;75(10):1206-14. PMID: 29913017.

20

Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG, et al. Injectable daxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Pract. 2018;5(3):273-82. PMID: 30009213.

41

Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018;147:84-8. PMID: 28888928.

0     

Jankovic J. Essential Tremor. N Engl J Med. 2018;379(6):595. PMID: 30091352.

8

Jankovic J. Immunologic treatment of Parkinson's disease. Immunotherapy. 2018;10(2):81-4. PMID: 29260621.

7

Jankovic J. Parkinson's disease tremors and serotonin. Brain. 2018;141(3):624-6. PMID: 30063797.

43

Jinnah HA, Albanese A, Bhatia KP, Cardoso F, Da Prat G, de Koning TJ, et al. Treatable inherited rare movement disorders. Mov Disord. 2018;33(1):21-35. PMID: 28861905.

9

Junker J, Brandt V, Berman BD, Vidailhet M, Roze E, Weissbach A, et al. Predictors of alcohol responsiveness in dystonia. Neurology. 2018;91(21):e2020-26. PMID: 30341158.

0     

Kamble N, Netravathi M, Nagaraju BC, Lenka A, Kumar K, Sowmya V, et al. Evaluation of cognition and cortical excitability in Huntington's disease. Can J Neurol Sci. 2018;45(2):176-81. PMID: 29307324.

0     

Lenka A, Herath P, Mittal SO, Pal PK. Sleep disturbances in patients with Parkinson's disease: It's time to wake up! Ann Mov Disord. 2018;1(1):8-19. DOI: 10.4103/AOMD.AOMD_16_18.

0     

Lenka A, Ingalhalikar M, Shah A, Saini J, Arumugham SS, Hegde S, et al. Hippocampal subfield atrophy in patients with Parkinson's disease and psychosis. J Neural Transm (Vienna). 2018;125(9):1361-1372. PMID: 29858658.

0     

Lenka A, Jhunjhunwala KR, Stezin A, Manjunath M, Srinivas D, Yadav R, et al. Implications of secondary unresponsiveness to dopaminergic drugs with preserved response to subthalamic nucleus stimulation in Parkinson's disease. Neurol India. 2018;66(Suppl):S135-7. PMID: 29503336.

0     

Lenka A, Reddy YCJ, Pal PK. Isolated tactile hallucination in a patient with Parkinson's disease: Quetiapine conquers the snakes and stones. Asian J Psychiatr. 2018;35:34-5. PMID: 29754101.

5

Lotia M, York MK, Strutt AM, Jankovic J. Leg stereotypy syndrome: Phenomenology and prevalence. J Neurol Neurosurg Psychiatry. 2018;89(7):692-5. PMID: 29332008.

5

Machol K, Jankovic J, Vijayakumar D, Burrage LC, Jain M, Lewis RA, et al. Atypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma. Neurol Genet. 2018;4(4):e248. PMID: 30046660.

5

Mahajan A, Jankovic J, Marsh L, Patel A, Jinnah HA, Comella C, et al. Cervical dystonia and substance abuse. J Neurol. 2018;265(4):970-5. PMID: 29569175.

23

Margraf NG, Wolke R, Granert O, Berardelli A, Bloem BR, Djaldetti R, et al. Consensus for the measurement of the camptocormia angle in the standing patient. Parkinsonism Relat Disord. 2018;52:1-5. PMID: 29907329.

23

Niemann N, Jankovic J. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018;10(7):. PMID: 30029483.

0     

Niemann N, Jankovic J. Correction to: Treatment of tardive dyskinesia: A general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018;78(5):609. PMID: 29524074.

32

Niemann N, Jankovic J. Treatment of tardive dyskinesia: A general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018;78(5):525-41. PMID: 29484607.

15

Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. Neurology. 2018;90(7):e559-e564. PMID: 29343468.

2

Oshima M, Deitiker P, Jankovic J, Atassi MZ. The regions on the light chain of botulinum neurotoxin type a recognized by t cells from toxin-treated cervical dystonia patients. The complete human t-cell recognition map of the toxin molecule. Immunol Invest. 2018;47(1):18-39. PMID: 28891721.

12

Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, et al. Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord. 2018;33(3):468-72. PMID: 29460982.

0     

Prasad S, Lenka A, Pal PK. Speech induced cervical dystonia: An unusual task specific dystonia. Parkinsonism Relat Disord. 2018;46:100-1. PMID: 29174183.

0     

Prasad S, Lenka A, Stezin A, Naduthota RM, Jha M, Yadav R, et al. A comparative study of early and late onset freezing of gait in Parkinson's disease. Ann Indian Acad Neurol. 2018;21(4):256-62. PMID: 30532353.

0     

Prasad S, Stezin A, Lenka A, George L, Saini J, Yadav R, et al. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease. Eur J Neurol. 2018;25(4):680-6. PMID: 29341412.

37

Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35-42. PMID: 29506749.

0     

Stezin A, Naduthota RM, Botta R, Varadharajan S, Lenka A, Saini J, et al. Clinical utility of visualisation of nigrosome-1 in patients with Parkinson's disease. Eur Radiol. 2018;28(2):718-26. PMID: 28779393.

26

Tarakad A, Jankovic J. Essential tremor and Parkinson's disease: Exploring the relationship. Tremor Other Hyperkinet Mov (N Y). 2018;8:589. PMID: 30643667.

9

Tarakad A, Jimenez-Shahed J. VMAT2 Inhibitors in Neuropsychiatric Disorders. CNS Drugs. 2018;32(12):1131-44. PMID: 30306450.

28

Telkes I, Viswanathan A, Jimenez-Shahed J, Abosch A, Ozturk M, Gupte A, et al. Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease. Proc Natl Acad Sci U S A. 2018;115(36):E8567-76. PMID: 30131429.

0     

Anandan C, Khuder SA, Koffman BM. Prevalence of autonomic dysfunction in hospitalized patients with Guillain-Barre syndrome. Muscle Nerve. 2017;56(2):331-3. PMID: 28039863.

13

Baizabal-Carvallo JF, Jankovic J. Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. J Neurol. 2017;264(2):359-63. PMID: 27942912.

5

Baizabal-Carvallo JF, Jankovic J. Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. J Neurol Neurosurg Psychiatry. 2017;88(5):453-5. PMID: 27986829.

8

Baizabal-Carvallo JF, Jankovic J. Functional (psychogenic) stereotypies. J Neurol. 2017;264(7):1482-7. PMID: 28653211.

42

Berman BD, Junker J, Shelton E, Sillau SH, Jinnah HA, Perlmutter JS, et al. Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017;88(7):595-602. PMID: 28438790.

7

Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, et al. Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;35:75-81. PMID: 28007518.

48

Carecchio M, Mencacci NE, Iodice A, Pons R, Panteghini C, Zorzi G, et al. ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord. 2017;41:37-43. PMID: 28511835.

1

Deitiker P, Oshima M, Jankovic J, Atassi MZ. Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. Immunol Lett. 2017;190:257-64. PMID: 28823519.

23

Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977-82. PMID: 28692723.

1

Jankovic J, Squitieri F. Letter re: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2017;88(3):334. PMID: 28093514.

81

Jankovic J. Botulinum toxin: State of the art. Mov Disord. 2017;32(8):1131-8. PMID: 28639368.

20

Jankovic J. Movement disorders in 2016: Progress in Parkinson disease and other movement disorders. Nat Rev Neurol. 2017;13(2):76-8. PMID: 28084323.

8

Jankovic J. Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease? Nat Rev Neurol. 2017;13(11):643-4. PMID: 28960185.

1

Jankovic J. Statin-related musculoskeletal pain in Parkinson's disease. Pain. 2017;158(9):1840. PMID: 28816887.

0     

Jhunjhunwala K, Kotikalapudi R, Lenka A, Thennarassu K, Yadav R, Saini J, et al. Abnormalities of eye-hand coordination in patients with writer's cramp: Possible role of the cerebellum. Tremor Other Hyperkinet Mov (N Y). 2017;7:499. PMID: 29109905.

27

Kanaan RA, Duncan R, Goldstein LH, Jankovic J, Cavanna AE. Are psychogenic non-epileptic seizures just another symptom of conversion disorder? J Neurol Neurosurg Psychiatry. 2017;88(5):425-9. PMID: 28235779.

0     

Lenka A, Benito-Leon J, Louis ED. Is there a premotor phase of essential tremor? Tremor Other Hyperkinet Mov (N Y). 2017;7:498. PMID: 29051842.

0     

Lenka A, Bhalsing KS, Panda R, Jhunjhunwala K, Naduthota RM, Saini J, et al. Role of altered cerebello-thalamo-cortical network in the neurobiology of essential tremor. Neuroradiology. 2017;59(2):157-68. PMID: 28062908.

0     

Lenka A, George L, Arumugham SS, Hegde S, Reddy V, Kamble N, et al. Predictors of onset of psychosis in patients with Parkinson's disease: Who gets it early? Parkinsonism Relat Disord. 2017;44:91-4. PMID: 28928050.

0     

Lenka A, Hegde S, Arumugham SS, Pal PK. Pattern of cognitive impairment in patients with Parkinson's disease and psychosis: A critical review. Parkinsonism Relat Disord. 2017;37:11-8. PMID: 28057432.

0     

Lenka A, Herath P, Christopher R, Pal PK. Psychosis in Parkinson's disease: From the soft signs to the hard science. J Neurol Sci. 2017;379:169-76. PMID: 28716235.

0     

Lenka A, Jhunjhunwala KR, Panda R, Saini J, Bharath RD, Yadav R, et al. Altered brain network measures in patients with primary writing tremor. Neuroradiology. 2017;59(10):1021-9. PMID: 28779337.

0     

Lenka A, Padmakumar C, Pal PK. Treatment of older Parkinson's disease. Int Rev Neurobiol. 2017;132:381-405. PMID: 28554416.

0     

Lenka A, Pal PK, Bhatti DE, Louis ED. Pathogenesis of primary orthostatic tremor: Current concepts and controversies. Tremor Other Hyperkinet Mov (N Y). 2017;7:513. PMID: 29204315.

0     

Lenka A, Pal PK. "Miro" in Parkinson's disease: Here, there, everywhere! Mov Disord. 2017;32(6):839. PMID: 28597558.

0     

Lenka A, Pasha SA, Mangalore S, George L, Jhunjhunwala KR, Bagepally BS, et al. Role of corpus callosum volumetry in differentiating the subtypes of progressive supranuclear palsy and early Parkinson's disease. Mov Disord Clin Pract. 2017;4(4):552-8. PMID: 30363434.

0     

Lenka A, Thota N, Stezin A, Pal PK, Yadav R. Orofacial involuntary movements in neurosyphilis: Beyond the candy sign. Tremor Other Hyperkinet Mov (N Y). 2017;7:507. PMID: 29090106.

0     

Louis ED, Lenka A. The olivary hypothesis of essential tremor: Time to lay this model to rest? Tremor Other Hyperkinet Mov (N Y). 2017;7:473. PMID: 28966877.

0     

Manjunath M, Yadav R, Dwarakanath S, Jhunjhunwala K, Jafar A, Surathi P, et al. Experience of pallidal deep brain stimulation in dystonia at a tertiary care centre in India: An initial experience. Neurol India. 2017;65(6):1322-9. PMID: 29133709.

69

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88(2):152-9. PMID: 27913695.

0     

Naduthota RM, Honnedevasthana AA, Lenka A, Saini J, Geethanath S, Bharath RD, et al. Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease. J Neurol Sci. 2017;382:61-5. PMID: 29111022.

146

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017;32(9):1264-310. PMID: 28887905.

25

Pirio Richardson S, Altenmuller E, Alter K, Alterman RL, Chen R, Frucht S, et al. Research priorities in limb and task-specific dystonias. Front Neurol. 2017;8:170. PMID: 28515706.

173

Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain. 2017;140(12):3191-203. PMID: 29140481.

21

Robledo I, Jankovic J. Media hype: Patient and scientific perspectives on misleading medical news. Mov Disord. 2017;32(9):1319-23. PMID: 28370445.

12

Rousseaux MWC, Shulman JM, Jankovic J. Progress toward an integrated understanding of Parkinson's disease. F1000Res. 2017;6:1121. PMID: 28751973.

0     

Sauerbier A, Lenka A, Aris A, Pal PK. Nonmotor symptoms in Parkinson's disease: Gender and ethnic differences. Int Rev Neurobiol. 2017;133:417-46. PMID: 28802927.

91

Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017;74(2):216-24. PMID: 27942720.

0     

Shah A, Lenka A, Saini J, Wagle S, Naduthota RM, Yadav R, et al. Altered brain wiring in Parkinson's disease: A structural connectome-based analysis. Brain Connect. 2017;7(6):347-56. PMID: 28595456.

0     

Stezin A, Lenka A, Jhunjhunwala K, Saini J, Pal PK. Advanced structural neuroimaging in progressive supranuclear palsy: Where do we stand? Parkinsonism Relat Disord. 2017;36:19-32. PMID: 28057431.

34

Tarakad A, Jankovic J. Anosmia and Ageusia in Parkinson's Disease. Int Rev Neurobiol. 2017;133:541-56. PMID: 28802932.

54

Tarakad A, Jankovic J. Diagnosis and management of Parkinson's disease. Semin Neurol. 2017;37(2):118-26. PMID: 28511252.

0     

Thomas M, Lenka A, Kumar Pal P. Handwriting analysis in Parkinson's disease: Current status and future directions. Mov Disord Clin Pract. 2017;4(6):806-18. PMID: 30363367.

0     

Thota N, Lenka A, George L, Hegde S, Arumugham SS, Prasad S, et al. Impaired frontal lobe functions in patients with Parkinson's disease and psychosis. Asian J Psychiatr. 2017;30:192-5. PMID: 29101795.

36

Troster AI, Jankovic J, Tagliati M, Peichel D, Okun MS. Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord. 2017;32(3):433-40. PMID: 27753157.

8

Vijayakumar D, Wijemanne S, Jankovic J. Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017;372:57-9. PMID: 28017248.

35

Wharen RE, Jr, Okun MS, Guthrie BL, Uitti RJ, Larson P, et al. Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial. Parkinsonism Relat Disord. 2017;40:18-26. PMID: 28400200.

15

Wijemanne S, Vijayakumar D, Jankovic J. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017;376:129-32. PMID: 28431598.

18

Alam M, Sanghera MK, Schwabe K, Lutjens G, Jin X, Song J, et al. Globus pallidus internus neuronal activity: A comparative study of linear and non-linear features in patients with dystonia or Parkinson's disease. J Neural Transm (Vienna). 2016;123(3):231-40. PMID: 26597125.

4

Albanese A, Bhatia K, DeLong MR, Fahn S, Fung VS, Hallett M, et al. "Complex" dystonia is not a category in the new 2013 consensus classification. Mov Disord. 2016;31(11):1758-9. PMID: 27612445.

2

Baizabal-Carvallo JF, Jankovic J. Functional (psychogenic) saccadic oscillations and oculogyric crises. Lancet Neurol. 2016;15(8):791. PMID: 27302355.

48

Baizabal-Carvallo JF, Jankovic J. Movement disorders induced by deep brain stimulation. Parkinsonism Relat Disord. 2016;25:1-9. PMID: 26806438.

60

Baizabal-Carvallo JF, Jankovic J. Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol. 2016;12(3):175-85. PMID: 26891767.

9

Baizabal-Carvallo JF, Jankovic J. Psychogenic ophthalmologic movement disorders. J Neuropsychiatry Clin Neurosci. 2016;28(3):195-8. PMID: 26792096.

19

Comella CL, Perlmutter JS, Jinnah HA, Waliczek TA, Rosen AR, Galpern WR, et al. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016;31(4):563-9. PMID: 26971359.

113

Deng HX, Shi Y, Yang Y, Ahmeti KB, Miller N, Huang C, et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016;48(7):733-9. PMID: 27270108.

45

Farlow JL, Robak LA, Hetrick K, Bowling K, Boerwinkle E, Coban-Akdemir ZH, et al. Whole-exome sequencing in familial Parkinson disease. JAMA Neurol. 2016;73(1):68-75. PMID: 26595808.

108

Huntington Study Group , Frank S, Testa CM, Stamler D, Kayson E, Davis C, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial. Jama. 2016;316(1):40-50. PMID: 27380342.

29

Huntington Study Group Pharos Investigators , Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, et al. Clinical-genetic associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for clinical trials. JAMA Neurol. 2016;73(1):102-10. PMID: 26569098.

78

Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461-70. PMID: 27819145.

6

Jankovic J. Leg stereotypy disorder. J Neurol Neurosurg Psychiatry. 2016;87(2):220-1. PMID: 26209715.

0     

Jhunjhunwala K, George L, Kotikalapudi R, Gupta PK, Lenka A, Stezin A, et al. A preliminary study of the neuroanatomical correlates of primary writing tremor: Role of cerebellum. Neuroradiology. 2016;58(8):827-36. PMID: 27216204.

0     

Lauro PM, Vanegas-Arroyave N, Huang L, Taylor PA, Zaghloul KA, Lungu C, et al. DBSproc: An open source process for DBS electrode localization and tractographic analysis. Hum Brain Mapp. 2016;37(1):422-33. PMID: 26523416.

27

LeDoux MS, Vemula SR, Xiao J, Thompson MM, Perlmutter JS, Wright LJ, et al. Clinical and genetic features of cervical dystonia in a large multicenter cohort. Neurol Genet. 2016;2(3):e69. PMID: 27123488.

0     

Lenka A, Arumugham SS, Christopher R, Pal PK. Genetic substrates of psychosis in patients with Parkinson's disease: A critical review. J Neurol Sci. 2016;364:33-41. PMID: 27084212.

0     

Lenka A, Hegde S, Jhunjhunwala KR, Pal PK. Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: A review. Parkinsonism Relat Disord. 2016;22:1-8. PMID: 26639978.

0     

Lenka A, Naduthota RM, Jha M, Panda R, Prajapati A, Jhunjhunwala K, et al. Freezing of gait in Parkinson's disease is associated with altered functional brain connectivity. Parkinsonism Relat Disord. 2016;24:100-6. PMID: 26776567.

14

Lotia M, Jankovic J. Botulinum Toxin for the Treatment of Tremor and Tics. Semin Neurol. 2016;36(1):54-63. PMID: 26866497.

26

Lotia M, Jankovic J. New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother. 2016;17(7):895-909. PMID: 26830844.

0     

McGinley BM, Kirkness JP, Schneider H, Lenka A, Smith PL, Schwartz AR. Utilizing inspiratory airflows during standard polysomnography to assess pharyngeal function in children during sleep. Pediatr Pulmonol. 2016;51(4):431-8. PMID: 26474407.

22

Molho ES, Stacy M, Gillard P, Charles D, Adler CH, Jankovic J, et al. Impact of cervical dystonia on work productivity: An analysis from a patient registry. Mov Disord Clin Pract. 2016;3(2):130-8. PMID: 27774495.

54

Muller SH, Girard SL, Hopfner F, Merner ND, Bourassa CV, Lorenz D, et al. Genome-wide association study in essential tremor identifies three new loci. Brain. 2016;139(Pt 12):3163-9. PMID: 27797806.

6

Oshima M, Deitiker P, Jankovic J, Atassi MZ. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016;300:36-46. PMID: 27806874.

29

Pharos Investigators Huntington Study Group , Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, et al. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016;73(1):102-10. PMID: 26569098.

0     

Rossi PJ, Gunduz A, Judy J, Wilson L, Machado A, Giordano JJ, et al. Proceedings of the Third Annual Deep Brain Stimulation Think Tank: A review of emerging issues and technologies. Front Neurosci. 2016;10:119. PMID: 27092042.

269

Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-26. PMID: 27164716.

0     

Stezin A, George L, Jhunjhunwala K, Lenka A, Saini J, Netravathi M, et al. Exploring cortical atrophy and its clinical and biochemical correlates in Wilson's disease using voxel based morphometry. Parkinsonism Relat Disord. 2016;30:52-7. PMID: 27372240.

8

Thenganatt MA, Jankovic J. Psychogenic (functional) parkinsonism. Handb Clin Neurol. 2016;139:259-62. PMID: 27719845.

16

Thenganatt MA, Jankovic J. Recent advances in understanding and managing Tourette syndrome. F1000Res. 2016;5:. PMID: 26918185.

0     

Thenganatt MA, Jankovic J. Response to Shill and colleagues. Parkinsonism Relat Disord. 2016;23:108. PMID: 26639977.

72

Thenganatt MA, Jankovic J. The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2016;22 Suppl 1:S162-5. PMID: 26522219.

0     

Vanegas N, Zaghloul K, Hallett M, Lungu C. Leg movements during general anesthesia. Mov Disord Clin Pract. 2016;3(5):510-2. PMID: 28239614.

0     

Vanegas-Arroyave N, Lauro PM, Huang L, Hallett M, Horovitz SG, Zaghloul KA, et al. Tractography patterns of subthalamic nucleus deep brain stimulation. Brain. 2016;139(Pt 4):1200-10. PMID: 26921616.

0     

Vanegas-Arroyave N, Panyakaew P, Lamichhane D, Shulman L, Hallett M. Possible functional moving toes syndrome. Tremor Other Hyperkinet Mov (N Y). 2016;6:352. PMID: 27144090.

65

Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 1: Treatment of levodopa-induced dyskinesia. Drugs. 2016;76(7):759-77. PMID: 27091215.

40

Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: Treatment of tardive dyskinesia. Drugs. 2016;76(7):779-87. PMID: 27091214.

18

Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. Headache. 2016;56(1):153-61. PMID: 26573884.

61

Ashoori A, Eagleman DM, Jankovic J. Effects of auditory rhythm and music on gait disturbances in Parkinson's disease. Front Neurol. 2015;6:234. PMID: 26617566.

46

Baizabal-Carvallo JF, Cardoso F, Jankovic J. Myorhythmia: Phenomenology, etiology, and treatment. Mov Disord. 2015;30(2):171-9. PMID: 25487777.

21

Baizabal-Carvallo JF, Jankovic J. Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015;262(11):2420-4. PMID: 26194199.

85

Baizabal-Carvallo JF, Jankovic J. Stiff-person syndrome: Insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry. 2015;86(8):840-8. PMID: 25511790.

6

Baizabal-Carvallo JF, Xia G, Botros P, Laguna J, Ashizawa T, Jankovic J. Bolivian kindred with combined spinocerebellar ataxia types 2 and 10. Acta Neurol Scand. 2015;132(2):139-42. PMID: 25630585.

73

Byrne S, Walsh C, Hacohen Y, Muscal E, Jankovic J, Stocco A, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e130. PMID: 26236759.

38

Calleo JS, Amspoker AB, Sarwar AI, Kunik ME, Jankovic J, Marsh L, et al. A pilot study of a cognitive-behavioral treatment for anxiety and depression in patients with Parkinson disease. J Geriatr Psychiatry Neurol. 2015;28(3):210-7. PMID: 26047635.

20

Deng H, Wu Y, Jankovic J. The EIF4G1 gene and Parkinson's disease. Acta Neurol Scand. 2015;132(2):73-8. PMID: 25765080.

21

Deng H, Xiu X, Jankovic J. Genetic convergence of Parkinson's disease and lysosomal storage disorders. Mol Neurobiol. 2015;51(3):1554-68. PMID: 25099932.

19

Deng H, Zheng W, Jankovic J. Genetics and molecular biology of brain calcification. Ageing Res Rev. 2015;22:20-38. PMID: 25906927.

74

Feng Y, Jankovic J, Wu YC. Epigenetic mechanisms in Parkinson's disease. J Neurol Sci. 2015;349(1-2):3-9. PMID: 25553963.

47

Feng Y, Liu T, Dong SY, Guo YJ, Jankovic J, Xu H, et al. Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells. J Neurochem. 2015;134(4):668-76. PMID: 25991017.

41

Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, et al. Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). J Neurol Sci. 2015;349(1-2):84-93. PMID: 25595221.

4

Jankovic J, Bressman S, Dauer W, Kang UJ. Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Mov Disord. 2015;30(14):1862-9. PMID: 26477883.

30

Jankovic J. Gait disorders. Neurol Clin. 2015;33(1):249-68. PMID: 25432732.

1

Jankovic J. Movement disorders. Neurol Clin. 2015;33(1):xv-xvi. PMID: 25432734.

22

Jankovic J. Therapeutic developments for tics and myoclonus. Mov Disord. 2015;30(11):1566-73. PMID: 26315614.

0     

Jhunjhunwala K, Lenka A, Pal PK. A clinical profile of 125 patients with writer's cramp. Eur Neurol. 2015;73(5-6):316-20. PMID: 25997562.

25

Jost WH, Benecke R, Hauschke D, Jankovic J, Kanovsky P, Roggenkamper P, et al. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015;9:1913-26. PMID: 25897202.

64

Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015;30(3):313-27. PMID: 25649017.

0     

Lenka A, Bhalsing KS, Jhunjhunwala KR, Chandran V, Pal PK. Are patients with limb and head tremor a clinically distinct subtype of essential tremor? Can J Neurol Sci. 2015;42(3):181-6. PMID: 25857448.

0     

Lenka A, Jhunjhunwala KR, Saini J, Pal PK. Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: A critical review. Parkinsonism Relat Disord. 2015;21(7):683-91. PMID: 25920541.

0     

Lenka A, Kamble NL, Sowmya V, Jhunjhunwala K, Yadav R, Netravathi M, et al. Determinants of onset of Huntington's disease with behavioral symptoms: insight from 92 patients. J Huntingtons Dis. 2015;4(4):319-24. PMID: 26682993.

145

Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015;14(7):710-9. PMID: 26025783.

0     

Mailankody P, Battu R, Khanna A, Lenka A, Yadav R, Pal PK. Optical coherence tomography as a tool to evaluate retinal changes in Parkinson's disease. Parkinsonism Relat Disord. 2015;21(10):1164-9. PMID: 26297381.

158

Olanow CW, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015;78(2):248-57. PMID: 26061140.

0     

Park JE, Vanegas-Arroyave N, Hallett M, Lungu C. A woman with a novel mutation of THAP1 with a prominent response to deep brain stimulation of the globus pallidus internus. JAMA Neurol. 2015;72(11):1369. PMID: 26415042.

0     

Relja M, Jacinto J, Jankovic J, Albanese A. Botulinum neurotoxin revisited - An individualised, patient-centric approach for the treatment of dystonia and spasticity. Euro Neurol Rev. 2015;10(1):28-34.

33

Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, et al. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015;30(14):1885-92. PMID: 26260437.

51

Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, et al. Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Mov Disord. 2015;30(10):1371-81. PMID: 26095202.

36

Thenganatt MA, Jankovic J. Psychogenic movement disorders. Neurol Clin. 2015;33(1):205-24. PMID: 25432730.

0     

Vanegas N, Zaghloul KA. Deep brain stimulation for substance abuse. Curr Behav Neurosci Rep. 2015;2(2):72-9. DOI: 10.1007/s40473-015-0037-2.

42

Waln O, Jankovic J. Paroxysmal movement disorders. Neurol Clin. 2015;33(1):137-52. PMID: 25432727.

11

Waln O, Wu Y, Perlman R, Wendt J, Van AK, Jankovic J. Dopamine transporter imaging in essential tremor with and without parkinsonian features. J Neural Transm (Vienna). 2015;122(11):1515-21. PMID: 26133163.

167

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. 2015;30(7):919-27. PMID: 25737166.

133

Wijemanne S, Jankovic J. Dopa-responsive dystonia-clinical and genetic heterogeneity. Nat Rev Neurol. 2015;11(7):414-24. PMID: 26100751.

21

Wijemanne S, Jankovic J. Movement disorders in catatonia. J Neurol Neurosurg Psychiatry. 2015;86(8):825-32. PMID: 25411548.

39

Wijemanne S, Jankovic J. Restless legs syndrome: Clinical presentation diagnosis and treatment. Sleep Med. 2015;16(6):678-90. PMID: 25979181.

82

Yu D, Mathews CA, Scharf JM, Neale BM, Davis LK, Gamazon ER, et al. Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015;172(1):82-93. PMID: 25158072.

1

Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Reply: Dystonia after severe head injuries. Mov Disord. 2014;29(4):578-9. PMID: 24590449.

3

Baizabal-Carvallo JF, Jankovic J. Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2014;17(1):104-6. PMID: 23663196.

41

Baizabal-Carvallo JF, Jankovic J. The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014;85(5):573-5. PMID: 24259592.

107

Baizabal-Carvallo JF, Kagnoff MN, Jimenez-Shahed J, Fekete R, Jankovic J. The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry. 2014;85(5):567-72. PMID: 24096713.

6

Black KJ, Jankovic J, Hershey T, McNaught KS, Mink JW, Walkup J. Progress in research on Tourette syndrome. J Obsessive Compuls Relat Disord. 2014;3(4):359-62. PMID: 25436182.

43

Charles PD, Adler CH, Stacy M, Comella C, Jankovic J, Manack Adams A, et al. Cervical dystonia and pain: Characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014;261(7):1309-19. PMID: 24752807.

149

Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neurol. 2014;10(6):337-48. PMID: 24840975.

21

DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: Systematic literature review, case report, and assessment of stimulation threshold safety. Neuromodulation. 2014;17(5):405-18; discussion 418. PMID: 24947418.

30

Evidente VGH, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014;346(1-2):116-20. PMID: 25186131.

0     

Factor SA, Jankovic J. Editorial: Neurotherapeutics of movement disorders. Neurotherapeutics. 2014;11(1):3-5. PMID: 24366609.

6

Factor SA, Jankovic J. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014;83(15):1388-9. PMID: 25288700.

51

Feng Y, Liu T, Li XQ, Liu Y, Zhu XY, Jankovic J, et al. Neuroprotection by Orexin-A via HIF-1alpha induction in a cellular model of Parkinson's disease. Neurosci Lett. 2014;579:35-40. PMID: 25038418.

0     

Fernandez HH, Jankovic J, Holds JB, Lin D, Burns J, Verma A, et al. Observational study of incobotulinumtoxina for cervical dystonia or blepharospasm (XCiDaBLE): Interim results for the first 170 subjects with blepharospasm. Tremor Other Hyperkinet Mov (N Y). 2014;4:238. PMID: 25120942.

14

Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, et al. Designing clinical trials for dystonia. Neurotherapeutics. 2014;11(1):117-27. PMID: 24282121.

15

Giladi N, Ghys L, Surmann E, Boroojerdi B, Jankovic J. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014;20(12):1345-51. PMID: 25444083.

13

Gilbert DL, Jankovic J. Pharmacological treatment of Tourette syndrome. J Obsessive-Compulsive Relat Disord. 2014;3(4):407-14. DOI: 10.1016/j.jocrd.2014.04.006.

31

Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, et al. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014;29(9):1171-80. PMID: 24838182.

19

Hauser RA, Isaacson S, Clinch T, Tigan/Apokyn Study Investigators. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014;20(11):1171-6. PMID: 25239603.

16

Inzelberg R, Hassin-Baer S, Jankovic J. Genetic movement disorders in patients of Jewish ancestry. JAMA Neurol. 2014;71(12):1567-72. PMID: 25347348.

22

Jankovic J, Berkovich E, Eyal E, Tolosa E. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord. 2014;20(6):640-3. PMID: 24637126.

35

Jankovic J, Roos RA. Chorea associated with Huntington's disease: To treat or not to treat? Mov Disord. 2014;29(11):1414-8. PMID: 25156927.

24

Jankovic J, Sherer T. The future of research in Parkinson disease. JAMA Neurol. 2014;71(11):1351-2. PMID: 25178587.

18

Jankovic J. "Psychogenic" versus "functional" movement disorders? That is the question. Mov Disord. 2014;29(13):1697-8. PMID: 25255973.

72

Le W, Sayana P, Jankovic J. Animal models of Parkinson's disease: A gateway to therapeutics? Neurotherapeutics. 2014;11(1):92-110. PMID: 24158912.

64

McGrath LM, Yu D, Marshall C, Davis LK, Thiruvahindrapuram B, Li B, et al. Copy number variation in obsessive-compulsive disorder and tourette syndrome: A cross-disorder study. J Am Acad Child Adolesc Psychiatry. 2014;53(8):910-9. PMID: 25062598.

10

Nutt JG, Siderowf AD, Guttman M, Schmidt PN, Zamudio JI, Wu SS, et al. Mobility, mood and site of care impact health related quality of life in Parkinson's disease. Parkinsonism Relat Disord. 2014;20(3):274-9. PMID: 24182524.

64

Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014;20(2):142-8. PMID: 24055014.

186

Parkinson Study Group QE Investigators , Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit. JAMA Neurol. 2014;71(5):543-52. PMID: 24664227.

19

Patel AJ, Sarwar AI, Jankovic J, Viswanathan A. Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. World Neurosurg. 2014;82(1-2):241 e1-4. PMID: 24076056.

48

Patel N, Hanfelt J, Marsh L, Jankovic J, members of the Dystonia Coalition. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014;85(8):882-4. PMID: 24828895.

198

Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100-12. PMID: 24331796.

135

Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: A decade of the PREDICT-HD study. Front Aging Neurosci. 2014;6(APR):78. PMID: 24795630.

40

Pulliam CL, Eichenseer SR, Goetz CG, Waln O, Hunter CB, Jankovic J, et al. Continuous in-home monitoring of essential tremor. Parkinsonism Relat Disord. 2014;20(1):37-40. PMID: 24126021.

56

Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014;90:344-8. PMID: 25130293.

255

Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499-504. PMID: 24514863.

0     

Thenganatt MA, Jankovic J. Psychogenic tremor: a video guide to its distinguishing features. Tremor Other Hyperkinet Mov (N Y). 2014;4:253. PMID: 25243097.

45

Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11(1):139-52. PMID: 24142590.

30

Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014;29(1):126-30. PMID: 24150997.

0     

Yang AI, Vanegas N, Lungu C, Zaghloul KA. Beta-coupled high-frequency activity and beta-locked neuronal spiking in the subthalamic nucleus of Parkinson's disease. J Neurosci. 2014;34(38):12816-27. PMID: 25232117.

1077

Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-73. PMID: 23649720.

43

Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna). 2013;120(11):1579-89. PMID: 23580159.

14

Baizabal-Carvallo JF, Jankovic J, Feld J. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013;24(2):298-306. PMID: 23677449.

96

Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013;28(4):543-7. PMID: 23400857.

150

Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, et al. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013;9(10):e1003864. PMID: 24204291.

0     

Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 24255801.

55

Deng H, Gao K, Jankovic J. The VPS35 gene and Parkinson's disease. Mov Disord. 2013;28(5):569-75. PMID: 23536430.

38

Deng H, Liang H, Jankovic J. F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol. 2013;70(1):20-4. PMID: 23318512.

24

Dhungana S, Jankovic J. Yips and other movement disorders in golfers. Mov Disord. 2013;28(5):576-81. PMID: 23519739.

0     

Fernandez HH, Pagan F, Danisi F, Greeley D, Jankovic J, Verma A, et al. Prospective study evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm: Interim results from the first 145 subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 23724362.

0     

Fernandez HH, Pappert EJ, Comella CL, Evidente VG, Truong DD, Verma A, et al. Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naive subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 23610743.

139

Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94-114. PMID: 23380701.

91

Jankovic J. Medical treatment of dystonia. Mov Disord. 2013;28(7):1001-12. PMID: 23893456.

11

Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications. Expert Opin Orphan Drugs. 2013;1(5):423-36. DOI: 10.1517/21678707.2013.787358.

13

Kansara S, Trivedi A, Chen S, Jankovic J, Le W. Early diagnosis and therapy of Parkinson's disease: Can disease progression be curbed? J Neural Transm (Vienna). 2013;120(1):197-210. PMID: 22733089.

59

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, et al. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology. 2013;80(22):2022-7. PMID: 23624566.

0     

Louis ED, Bain PG, Hallett M, Jankovic J, Vonsattel JP. What is It? Difficult to Pigeon Hole Tremor: a Clinical-Pathological Study of a Man with Jaw Tremor. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 23864988.

30

Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210-5. PMID: 23280482.

123

Mehanna R, Jankovic J. Movement disorders in cerebrovascular disease. Lancet Neurol. 2013;12(6):597-608. PMID: 23602779.

50

Mehanna R, Jankovic J. Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci. 2013;328(1-2):1-8. PMID: 23522528.

0     

Mehanna R, Jankovic J. Restless legs syndrome and cerebrovascular disease - authors' reply. Lancet Neurol. 2013;12(8):734-5. PMID: 23867192.

63

Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013;67:141-52. PMID: 23178324.

0     

Olson DM, Grissom JL, Williamson RA, Bennett SN, Bellows ST, James ML. Interrater reliability of the bedside shivering assessment scale. Am J Crit Care. 2013;22(1):70-4. PMID: 23283091.

78

Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28(13):1775-83. PMID: 23868503.

53

Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013;5(2):249-66. PMID: 23381141.

117

Scharf JM, Yu D, Mathews CA, Neale BM, Stewart SE, Fagerness JA, et al. Genome-wide association study of Tourette's syndrome. Mol Psychiatry. 2013;18(6):721-8. PMID: 22889924.

92

Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol. 2013;11(1):59-79. PMID: 23814539.

0     

Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington's and other diseases. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 24255799.

352

Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Comparison with the Unified Parkinson's Disease Rating Scale. Mov Disord. 2013;28(5):668-70. PMID: 23408503.

13

Strickland BA, Jimenez-Shahed J, Jankovic J, Viswanathan A. Radiofrequency lesioning through deep brain stimulation electrodes: A pilot study of lesion geometry and temperature characteristics. J Clin Neurosci. 2013;20(12):1709-12. PMID: 24035651.

40

Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, et al. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin((R))) injections in blepharospasm. J Neural Transm (Vienna). 2013;120(9):1345-53. PMID: 23435927.

0     

Waln O, Jankovic J. An update on tardive dyskinesia: From phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 23858394.

9

Waln O, Jankovic J. Bilateral globus pallidus internus deep brain stimulation after bilateral pallidotomy in a patient with generalized early-onset primary dystonia. Mov Disord. 2013;28(8):1162-3. PMID: 23580321.

21

Waln O, Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013;28(12):1748-9. PMID: 23637028.

17

Atassi MZ, Jankovic J, Steward LE, Aoki KR, Dolimbek BZ. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012;217(1):17-27. PMID: 21962573.

55

Baizabal Carvallo JF, Mostile G, Almaguer M, Davidson A, Simpson R, Jankovic J. Deep brain stimulation hardware complications in patients with movement disorders: Risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012;90(5):300-6. PMID: 22797749.

71

Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord. 2012;27(8):935-46. PMID: 22555904.

1

Baizabal-Carvallo JF, Jankovic J. Spinocerebellar ataxia types 2 and 10: More than a coincidental association? Arch Neurol. 2012;69(11):1524-5; Author reply 1525. PMID: 23117922.

62

Deng H, Gao K, Jankovic J. The genetics of Tourette syndrome. Nat Rev Neurol. 2012;8(4):203-13. PMID: 22410579.

28

Deng H, Gu S, Jankovic J. LINGO1 variants in essential tremor and Parkinson's disease. Acta Neurol Scand. 2012;125(1):1-7. PMID: 21470193.

122

Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012;46(1):1-18. PMID: 22266337.

85

Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, et al. Reliability of a new scale for essential tremor. Mov Disord. 2012;27(12):1567-9. PMID: 23032792.

38

Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: A prospective, open-label extension study. Parkinsonism Relat Disord. 2012;18(5):488-93. PMID: 22326237.

36

Fekete R, Baizabal-Carvallo JF, Ha AD, Davidson A, Jankovic J. Convergence spasm in conversion disorders: Prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012;83(2):202-4. PMID: 21949106.

21

Fekete R, Jankovic J. Childhood stiff-person syndrome improved with rituximab. Case Rep Neurol. 2012;4(2):92-6. PMID: 22740823.

63

Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, et al. Head injury, alpha-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012;71(1):40-8. PMID: 22275250.

8

Guo Y, Deng X, Jankovic J, Su L, Zhang J, Le W, et al. Mutation screening of the HTR2B gene in patients with Tourette syndrome. Neurosci Lett. 2012;526(2):150-3. PMID: 22917605.

113

Ha AD, Jankovic J. Pain in Parkinson's disease. Mov Disord. 2012;27(4):485-91. PMID: 21953990.

119

Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol. 2012;25(4):433-47. PMID: 22691758.

5

Jankovic J. Current concepts in Parkinson's disease and other movement disorders. Curr Opin Neurol. 2012;25(4):429-32. PMID: 22772873.

30

Kurlan R, Crespi G, Coffey B, Mueller-Vahl K, Koval S, Wunderlich G, et al. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Mov Disord. 2012;27(6):775-8. PMID: 22407510.

0     

Laskowitz DT, Lei B, Dawson HN, Wang H, Bellows ST, Christensen DJ, et al. The apoE-mimetic peptide, COG1410, improves functional recovery in a murine model of intracerebral hemorrhage. Neurocrit Care. 2012;16(2):316-26. PMID: 21989844.

208

Lee HY, Huang Y, Bruneau N, Roll P, Roberson EDO, Hermann M, et al. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012;1(1):2-12. PMID: 22832103.

51

Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012;27(2):284-8. PMID: 22161845.

19

Li XP, Xie WJ, Zhang Z, Kansara S, Jankovic J, Le WD. A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration. Neurosignals. 2012;20(4):223-36. PMID: 22269801.

20

Marshall DF, Strutt AM, Williams AE, Simpson RK, Jankovic J, York MK. Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. Eur J Neurol. 2012;19(12):1525-31. PMID: 22632922.

13

Mehanna R, Jankovic J. Respiratory disorders associated with dystonia. Mov Disord. 2012;27(14):1816-9. PMID: 23208724.

23

Mostile G, Fekete R, Giuffrida JP, Yaltho T, Davidson A, Nicoletti A, et al. Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord. 2012;18(7):859-63. PMID: 22591578.

273

Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012;11(2):140-9. PMID: 22239915.

18

Ondo WG, Jankovic J, Simpson R, Jimenez-Shahed J. Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. Sleep Med. 2012;13(9):1202-4. PMID: 22995627.

62

Pan T, Zhu J, Hwu WJ, Jankovic J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012;7(9):e45183. PMID: 23028833.

0     

Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, et al. Meta-analysis of Parkinson's disease: Identification of a novel locus, RIT2. Ann Neurol. 2012;71(3):370-84. PMID: 22451204.

30

Patel SS, Jankovic J, Hood AJ, Jeter CB, Sereno AB. Reflexive and volitional saccades: Biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012;313(1-2):35-41. PMID: 22018763.

42

Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinson's disease. Curr Opin Neurol. 2012;25(4):448-59. PMID: 22772874.

33

Squitieri F, Jankovic J. Huntington's disease: How intermediate are intermediate repeat lengths? Mov Disord. 2012;27(14):1714-7. PMID: 23008174.

43

Strutt AM, Simpson R, Jankovic J, York MK. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol. 2012;19(1):121-7. PMID: 21668586.

56

Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: Target selection. Stereotact Funct Neurosurg. 2012;90(4):213-24. PMID: 22699684.

22

Zhang Z, Li X, Xie W, Tuo H, Hintermann S, Jankovic J, et al. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets. 2012;11(6):768-73. PMID: 22483304.

20

Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011;216(7):782-92. PMID: 21281977.

41

Baizabal Carvallo JF, Simpson R, Jankovic J. Diagnosis and treatment of complications related to deep brain stimulation hardware. Mov Disord. 2011;26(8):1398-406. PMID: 21714001.

25

Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011;58(1):1-7. PMID: 21620881.

88

Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S, US Xeomin Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1-2):103-9. PMID: 21764407.

88

Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN ®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1-2):103-9. PMID: 21764407.

11

Deitiker PR, Oshima M, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans. Autoimmunity. 2011;44(3):167-76. PMID: 20843162.

68

Fekete R, Jankovic J. Revisiting the relationship between essential tremor and Parkinson's disease. Mov Disord. 2011;26(3):391-8. PMID: 21462256.

17

Ferrara J, Stamey W, Strutt AM, Adam OR, Jankovic J. Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosci. 2011;23(2):141-8. PMID: 21677241.

13

Guo Y, Jankovic J, Song Z, Yang H, Zheng W, Le W, et al. LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett. 2011;487(2):174-6. PMID: 20951767.

18

Guo Y, Le WD, Jankovic J, Yang HR, Xu HB, Xie WJ, et al. Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord. 2011;26(9):1729-32. PMID: 21469209.

73

Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011;17(8):625-8. PMID: 21689962.

3

Ha AD, Jankovic J. An introduction to dyskinesia--the clinical spectrum. Int Rev Neurobiol. 2011;98:1-29. PMID: 21907081.

44

Ha AD, Jankovic J. Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med. 2011;123(5):116-21. PMID: 21904093.

1

Ha AD, Jankovic J. Parkinsonism and dystonia associated with adalimumab. Mov Disord. 2011;26(8):1556-8. PMID: 21495070.

54

Heldman DA, Jankovic J, Vaillancourt DE, Prodoehl J, Elble RJ, Giuffrida JP. Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord. 2011;17(7):537-42. PMID: 21570891.

347

Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699-705. PMID: 21685912.

19

Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, et al. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011;11:140. PMID: 22054223.

93

Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509-23. PMID: 22014129.

48

Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011;26(8):1521-8. PMID: 21520284.

126

Jankovic J, Kurlan R. Tourette syndrome: Evolving concepts. Mov Disord. 2011;26(6):1149-56. PMID: 21484868.

0     

Jankovic J, Yeeles K, Katsakou C, Amos T, Morriss R, Rose D, et al. Family caregivers' experiences of involuntary psychiatric hospital admissions of their relatives--a qualitative study. PLoS One. 2011;6(10):e25425. PMID: 22022393.

33

Jankovic J. Diagnosis and treatment of psychogenic parkinsonism. J Neurol Neurosurg Psychiatry. 2011;82(12):1300-3. PMID: 21933950.

0     

Kieburtz K, Parkinson Study Group PramiBID Investigators. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord. 2011;26(1):37-44. PMID: 20925067.

31

Le W, Nguyen D, Lin XW, Rawal P, Huang M, Ding Y, et al. Transcription factor PITX3 gene in Parkinson's disease. Neurobiol Aging. 2011;32(4):750-3. PMID: 19394114.

64

Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm. 2011;118(3):473-7. PMID: 21161300.

0     

Nopoulos PC, Aylward EH, Ross CA, Mills JA, Langbehn DR, Johnson HJ, et al. Smaller intracranial volume in prodromal Huntington's disease: Evidence for abnormal neurodevelopment. Brain. 2011;134(Pt 1):137-42. PMID: 20923788.

11

Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011;240-241:121-8. PMID: 22079193.

13

Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Human T-cell responses to botulinum neurotoxin: Proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011;237(1-2):66-72. PMID: 21737146.

101

Pan T, Li X, Jankovic J. The association between Parkinson's disease and melanoma. Int J Cancer. 2011;128(10):2251-60. PMID: 21207412.

0     

Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, et al. Copy number variation in familial Parkinson disease. PLoS One. 2011;6(8):e20988. PMID: 21829596.

637

Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95(4):629-35. PMID: 21930184.

55

Pena MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26(1):147-52. PMID: 20818603.

150

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): Prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415-23. PMID: 21482191.

289

Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69(3):570-80. PMID: 21400565.

18

Squitieri F, Esmaeilzadeh M, Ciarmiello A, Jankovic J. Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene. Mov Disord. 2011;26(5):925-7. PMID: 21370274.

0     

Sublette ME, Segal-Isaacson CJ, Cooper TB, Fekri S, Vanegas N, Galfalvy HC, et al. Validation of a food frequency questionnaire to assess intake of n-3 polyunsaturated fatty acids in subjects with and without major depressive disorder. J Am Diet Assoc. 2011;111(1):117-23 e1-2. PMID: 21185973.

59

van Rooijen DE, Geraedts EJ, Marinus J, Jankovic J, van Hilten JJ. Peripheral trauma and movement disorders: a systematic review of reported cases. J Neurol Neurosurg Psychiatry. 2011;82(8):892-8. PMID: 21493756.

75

Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. 2011;178(4):1509-16. PMID: 21435440.

54

Williams AE, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 2011;17(5):321-7. PMID: 21316292.

113

Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol. 2011;68(1):22-30. PMID: 21220674.

309

Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals. 2011;19(3):163-74. PMID: 21778691.

11

Yaltho TC, Jankovic J, Lotze T. The association of Tourette syndrome and dopa-responsive dystonia. Mov Disord. 2011;26(2):359-60. PMID: 21412842.

98

Yaltho TC, Jankovic J. The many faces of hemifacial spasm: Differential diagnosis of unilateral facial spasms. Mov Disord. 2011;26(9):1582-92. PMID: 21469208.

0     

Anderson KE, Gehl CR, Marder KS, Beglinger LJ, Paulsen JS, Huntington's Study Group. Comorbidities of obsessive and compulsive symptoms in Huntington's disease. J Nerv Ment Dis. 2010;198(5):334-8. PMID: 20458194.

0     

Beglinger LJ, O'Rourke JJ, Wang C, Langbehn DR, Duff K, Paulsen JS, et al. Earliest functional declines in Huntington disease. Psychiatry Res. 2010;178(2):414-8. PMID: 20471695.

11

Deng H, Yang H, Le W, Deng X, Xu H, Xiong W, et al. Examination of the MASH1 gene in patients with Parkinson's disease. Biochem Biophys Res Commun. 2010;392(4):548-50. PMID: 20097173.

2

Deng S, Deng H, Le W, Xu H, Yang H, Deng X, et al. Genetic analysis of the NEUROG2 gene in patients with Parkinson's disease. Neurosci Lett. 2010;468(3):195-7. PMID: 19879328.

36

DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up. Mov Disord. 2010;25(2):232-8. PMID: 20063387.

0     

Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology. 2010;75(6):500-7. PMID: 20610833.

0     

Elble RJ, Suchowersky O, Shaftman S, Weiner WJ, Huang P, Tilley B, et al. Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease. Mov Disord. 2010;25(8):1082-6. PMID: 20131372.

0     

Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord. 2010;16(6):423-6. PMID: 20338800.

16

Fekete R, Jankovic J. Psychogenic chorea associated with family history of Huntington disease. Mov Disord. 2010;25(4):503-4. PMID: 20063405.

25

Ferrara J, Diamond A, Hunter C, Davidson A, Almaguer M, Jankovic J. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81(3):315-9. PMID: 19726415.

44

Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs. 2010;70(5):561-71. PMID: 20329804.

0     

Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM, et al. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010;25(9):1190-4. PMID: 20629138.

443

Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010;133(Pt 3):713-26. PMID: 20157014.

76

Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev. 2010;29(1):79-125. PMID: 19358229.

40

Jankovic J, Gelineau-Kattner R, Davidson A. Tourette's syndrome in adults. Mov Disord. 2010;25(13):2171-5. PMID: 20690167.

108

Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70-3. PMID: 19726418.

53

Jankovic J. Camptocormia, head drop and other bent spine syndromes: Heterogeneous etiology and pathogenesis of parkinsonian deformities. Mov Disord. 2010;25(5):527-8. PMID: 20425791.

0     

Langbehn DR, Hayden MR, Paulsen JS, Predict-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):397-408. PMID: 19548255.

0     

Li C, Guo Y, Xie W, Li X, Jankovic J, Le W. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Neurochem Res. 2010;35(10):1546-56. PMID: 20635141.

15

Lim J, Sanghera MK, Darbin O, Stewart RM, Jankovic J, Simpson R. Nonlinear temporal organization of neuronal discharge in the basal ganglia of Parkinson's disease patients. Exp Neurol. 2010;224(2):542-4. PMID: 20653074.

434

Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164-72. PMID: 20970382.

74

Mehanna R, Jankovic J. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010;16(10):628-38. PMID: 20674459.

29

Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother. 2010;10(6):893-901. PMID: 20518606.

132

Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, et al. CSF A?42 and tau in Parkinson's disease with cognitive impairment. Movement Disorders. 2010;25(15):2682-5. PMID: 20818673.

44

Mostile G, Giuffrida JP, Adam OR, Davidson A, Jankovic J. Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord. 2010;25(12):1938-43. PMID: 20623687.

39

Mostile G, Jankovic J. Alcohol in essential tremor and other movement disorders. Mov Disord. 2010;25(14):2274-84. PMID: 20721919.

0     

Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, et al. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis. 2010;40(3):544-54. PMID: 20688164.

7

Okun MS, Lang A, Jankovic J. Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. Mov Disord. 2010;25(7):961-2; author reply 962-3. PMID: 20461816.

20

Ondo WG, Adam OR, Jankovic J, Chinnery PF. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord. 2010;25(14):2470-2. PMID: 20818611.

0     

Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82(3-4):201-7. PMID: 20385209.

53

Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord. 2010;25(15):2595-603. PMID: 20623772.

0     

Quaid KA, Swenson MM, Sims SL, Harrison JM, Moskowitz C, Stepanov N, et al. What were you thinking? Individuals at risk for Huntington Disease talk about having children. J Genet Couns. 2010;19(6):606-17. PMID: 20734119.

0     

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010;25(12):1801-8. PMID: 20669311.

127

Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010;480(1):78-82. PMID: 20540987.

0     

Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, et al. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC Med Genet. 2010;11:53. PMID: 20356410.

229

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Ann Neurol. 2010;68(1):18-27. PMID: 20582993.

96

Tan EK, Peng R, Teo YY, Tan LC, Angeles D, Ho P, et al. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010;31(5):561-8. PMID: 20186690.

98

Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316-23. PMID: 20359934.

88

Vilarino-Guell C, Wider C, Ross OA, Jasinska-Myga B, Kachergus J, Cobb SA, et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics. 2010;11(4):401-8. PMID: 20369371.

44

Wu Y, Davidson AL, Pan T, Jankovic J. Asian over-representation among patients with hemifacial spasm compared to patients with cranial-cervical dystonia. J Neurol Sci. 2010;298(1-2):61-3. PMID: 20864122.

81

Wu Y, Li X, Xie W, Jankovic J, Le W, Pan T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010;57(3):198-205. PMID: 20546814.

82

Xie W, Li X, Li C, Zhu W, Jankovic J, Le W. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J Neurochem. 2010;115(1):188-99. PMID: 20649845.

0     

York MK, Wilde E, Simpson R, Jankovic J. Acknowledgement of technological limitations while moving literature forward. J Neurol Sci. 2010;292(1-2):120. PMID: 20199780.

42

Zhu W, Li X, Xie W, Luo F, Kaur D, Andersen JK, et al. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis. 2010;37(2):307-13. PMID: 19818853.

8

Adam OR, Ferrara JM, Aguilar Tabora LG, Nashatizadeh MM, Negoita M, Jankovic J. Education research: Patient telephone calls in a movement disorders center: Lessons in physician-trainee education. Neurology. 2009;73(10):e50-2. PMID: 19738167.

9

Adam OR, Ferrara JM, Jankovic J. Motor-phonic tic mimicking essential palatal myoclonus. Mov Disord. 2009;24(13):2030-2. PMID: 19672987.

0     

Albanese A, Bigalke H, Foster K, Hallett M, Jankovic J, Montecucco C, et al. Foreword. Toxicon. 2009;54(5):549. DOI: 10.1016/j.toxicon.2009.02.004.

0     

Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, et al. Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT-HD study. Mov Disord. 2009;24(12):1763-72. PMID: 19562761.

3

Deng H, Zhu SH, Le WD, Yang HR, Lv HW, Xu HB, et al. Examination of the MSX1 gene in patients with Parkinson's disease. Acta Neurol Scand. 2009;120(6):442-4. PMID: 19922584.

67

Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol. 2009;256(3):320-32. PMID: 19224314.

14

Ferrara J, Jankovic J. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009;11(5):293-307. PMID: 19725596.

32

Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: A randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009;285(1-2):195-7. PMID: 19631949.

0     

Frank S, Huntington Study Group/TETRA-HD Investigators. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. BMC Neurol. 2009;9:62. PMID: 20021666.

0     

Freeman RD, Zinner SH, Muller-Vahl KR, Fast DK, Burd LJ, Kano Y, et al. Coprophenomena in Tourette syndrome. Dev Med Child Neurol. 2009;51(3):218-27. PMID: 19183216.

18

Guo Y, Jankovic J, Zhu S, Le W, Song Z, Xie W, et al. GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. Neurosci Lett. 2009;454(3):209-11. PMID: 19429085.

17

Gupta A, Jankovic J. Spinocerebellar ataxia 8: Variable phenotype and unique pathogenesis. Parkinsonism Relat Disord. 2009;15(9):621-6. PMID: 19559641.

4

Jankovic J, Albanese A, Hallett M. Unique properties of botulinum toxins. Toxicon. 2009;54(5):675. PMID: 19470348.

83

Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009;24(3):407-13. PMID: 19053054.

29

Jankovic J. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009;284(1-2):177-8. PMID: 19361809.

19

Jankovic J. Clinical efficacy and tolerability of Xeomin® in the treatment of blepharospasm. Eur J Neurol. 2009;16(Suppl 2):14-8. PMID: 20002742.

69

Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54(5):614-23. PMID: 19073203.

3

Jankovic J. Movement disorders. Preface. Neurol Clin. 2009;27(3):ix-x. PMID: 19555822.

62

Jankovic J. Peripherally induced movement disorders. Neurol Clin. 2009;27(3):821-32, vii. PMID: 19555833.

150

Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8(9):844-56. PMID: 19679276.

0     

Kloppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen JS, et al. Automatic detection of preclinical neurodegeneration: Presymptomatic Huntington disease. Neurology. 2009;72(5):426-31. PMID: 19188573.

0     

Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, et al. Genomewide association study for onset age in Parkinson disease. BMC Med Genet. 2009;10:98. PMID: 19772629.

61

Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: A new beginning? Neuroscientist. 2009;15(1):28-35. PMID: 19008336.

0     

Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I, et al. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology. 2009;73(5):385-92. PMID: 19652143.

0     

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, et al. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Mov Disord. 2009;24(16):2370-8. PMID: 19908310.

25

Mata IF, Hutter CM, Gonzalez-Fernandez MC, de Pancorbo MM, Lezcano E, Huerta C, et al. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009;10(4):347-53. PMID: 19308469.

43

Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S224-32. PMID: 20082997.

0     

Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;72(4):310-6. PMID: 18987351.

602

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-78. PMID: 19776408.

208

Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience. 2009;164(2):541-51. PMID: 19682553.

0     

Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology. 2009;73(4):279-86. PMID: 19636047.

0     

Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124(6):593-605. PMID: 18985386.

0     

Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563-70. PMID: 19433655.

26

Ravina B, Elm J, Camicioli R, Como PG, Marsh L, Jankovic J, et al. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009;24(9):1306-11. PMID: 19412939.

0     

Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, et al. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009;24(14):2081-90. PMID: 19691116.

29

Sitburana O, Wu LJ, Sheffield JK, Davidson A, Jankovic J. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009;15(10):758-61. PMID: 19505838.

19

Strutt AM, Lai EC, Jankovic J, Atassi F, Soety EM, Levin HS, et al. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009;71(5):551-8. PMID: 18514283.

83

Tagliati M, Jankovic J, Pagan F, Susatia F, Isaias IU, Okun MS. Safety of MRI in patients with implanted deep brain stimulation devices. Neuroimage. 2009;47 Suppl 2:T53-7. PMID: 19376247.

156

Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, et al. Occupation and risk of parkinsonism: A multicenter case-control study. Arch Neurol. 2009;66(9):1106-13. PMID: 19752299.

15

Wijemanne S, Jankovic J. Hemidystonia-hemiatrophy syndrome. Mov Disord. 2009;24(4):583-9. PMID: 19097182.

79

York MK, Wilde EA, Simpson R, Jankovic J. Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci. 2009;287(1-2):159-71. PMID: 19767016.

88

Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5(2):181-97. PMID: 18394562.

14

Ashoori A, Jankovic J. Mozart's movements and behaviour: a case of Tourette's syndrome? Postgrad Med J. 2008;84(992):313-7. PMID: 18644922.

26

Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008;45(15):3878-88. PMID: 18676021.

3

Atassi MZ, Jankovic J, Dolimbek BZ. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008;71(13):1040; author reply 1040-1. PMID: 18809844.

5

Azher SN, Jankovic J. Clinical aspects of progressive supranuclear palsy. Handb Clin Neurol. 2008;89:461-73. PMID: 18631769.

128

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353-60. PMID: 18546321.

23

Deng H, Le W, Shahed J, Xie W, Jankovic J. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett. 2008;430(1):18-22. PMID: 18068301.

7

Deng H, Le WD, Jankovic J. Genetic study of an American family with DYT3 dystonia (lubag). Neurosci Lett. 2008;448(2):180-3. PMID: 18952144.

5

Dulay MF, Strutt AM, Levin HS, Jankovic J, Lai EC, Grossman RG, et al. Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008;20(3):357-63. PMID: 18806240.

8

Erer S, Jankovic J. Adult onset tics after peripheral injury. Parkinsonism Relat Disord. 2008;14(1):75-6. PMID: 17292653.

53

Ferrara J, Jankovic J. Psychogenic movement disorders in children. Mov Disord. 2008;23(13):1875-81. PMID: 18709677.

48

Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31(3):127-33. PMID: 18520979.

2811

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70. PMID: 19025984.

120

Hallett M, Evinger C, Jankovic J, Stacy M, BEBRF International Workshop. Update on blepharospasm: Report from the BEBRF International Workshop. Neurology. 2008;71(16):1275-82. PMID: 18852443.

73

Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: The TREND-HD study. Arch Neurol. 2008;65(12):1582-9. PMID: 19064745.

127

Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008;4(4):743-57. PMID: 19043519.

55

Jankovic J, Ashoori A. Movement disorders in musicians. Mov Disord. 2008;23(14):1957-65. PMID: 18785647.

18

Jankovic J. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol. 2008;63(3):267-9. PMID: 18383071.

16

Jankovic J. Parkinson's disease and movement disorders: Moving forward. Lancet Neurol. 2008;7(1):9-11. PMID: 18093549.

2698

Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-76. PMID: 18344392.

72

Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48(3):379-84. PMID: 18223146.

76

Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008;115(4):585-91. PMID: 17558461.

1

Kenney C, Jankovic J. Reply: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2008;23(12):1793. PMID: 18709673.

11

Kuo SH, Jankovic J. Tardive gait. Clin Neurol Neurosurg. 2008;110(2):198-201. PMID: 17997030.

60

Kuo SH, Kenney C, Jankovic J. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord. 2008;23(4):616-9. PMID: 18181207.

99

Le W, Pan T, Huang M, Xu P, Xie W, Zhu W, et al. Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 2008;273(1-2):29-33. PMID: 18684475.

10

Molho E, Jankovic J, Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008;26 Suppl 1:43-53. PMID: 18603167.

130

Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. Mov Disord. 2008;23(15):2194-201. PMID: 18932271.

0     

Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, et al. Fear of health insurance loss among individuals at risk for Huntington disease. Am J Med Genet A. 2008;146A(16):2070-7. PMID: 18627059.

77

Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008;7(2):720-30. PMID: 18186601.

401

Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain. 2008;131(Pt 8):1969-78. PMID: 18187492.

176

Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis. 2008;32(1):16-25. PMID: 18640276.

21

Pan T, Zhu W, Zhao H, Deng H, Xie W, Jankovic J, et al. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 2008;1222:222-9. PMID: 18579122.

0     

Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, et al. Clinical correlates of depressive symptoms in familial Parkinson's disease. Mov Disord. 2008;23(15):2216-23. PMID: 18785635.

0     

Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington's disease decades before diagnosis: The Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874-80. PMID: 18096682.

0     

Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008;71(7):481-5. PMID: 18695158.

0     

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-23. PMID: 18413464.

318

Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699-706. PMID: 18458230.

27

Sitburana O, Jankovic J. Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci. 2008;266(1-2):31-3. PMID: 17888455.

0     

Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233-40. PMID: 18519872.

43

Stamey W, Davidson A, Jankovic J. Shoulder pain: A presenting symptom of Parkinson disease. J Clin Rheumatol. 2008;14(4):253-4. PMID: 18766134.

52

Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008;14(2):89-99. PMID: 18332838.

28

Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, et al. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008;14(1):77-80. PMID: 17433753.

34

Wu LJ, Sitburana O, Davidson A, Jankovic J. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008;23(16):2307-11. PMID: 18972544.

108

York MK, Dulay M, Macias A, Levin HS, Grossman R, Simpson R, et al. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008;79(7):789-95. PMID: 17965146.

216

Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526-9. PMID: 18343778.

51

Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 2008;105(5):1970-8. PMID: 18399960.

10

Adair JC, Cooke N, Jankovic J. Alexia without agraphia in Creutzfeldt-Jakob disease. J Neurol Sci. 2007;263(1-2):208-10. PMID: 17628601.

25

Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord. 2007;13 Suppl 3:S362-8. PMID: 18267265.

16

Ashoori A, Jankovic J. Mozart's movements and behaviour: A case of Tourette's syndrome? J Neurol Neurosurg Psychiatry. 2007;78(11):1171-5. PMID: 17940168.

4

Atassi MZ, Dolimbek BZ, Deitiker P, Jankovic J, Aoki KR. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007;20(1):15-21. PMID: 16981247.

101

Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord. 2007;22(12):1743-50. PMID: 17566119.

10

Deng H, Le W, Huang M, Xie W, Pan T, Jankovic J. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett. 2007;419(2):104-7. PMID: 17482357.

126

Deng H, Le W, Jankovic J. Genetics of essential tremor. Brain. 2007;130(Pt 6):1456-64. PMID: 17353225.

24

Deng H, Le WD, Hunter CB, Mejia N, Xie WJ, Jankovic J. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007;64(3):421-4. PMID: 17353387.

13

Diamond A, Kenney C, Almaguer M, Jankovic J. Hyperhidrosis due to deep brain stimulation in a patient with essential tremor. Case report. J Neurosurg. 2007;107(5):1036-8. PMID: 17977278.

22

Diamond A, Shahed J, Jankovic J. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007;260(1-2):199-203. PMID: 17561121.

64

Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007;44(5):1029-41. PMID: 16647121.

4

Erer S, Jankovic J. Hereditary chin tremor in Parkinson's disease. Clin Neurol Neurosurg. 2007;109(9):784-5. PMID: 17618046.

163

Freeman RD, Tourette Syndrome International Database Consortium. Tic disorders and ADHD: Answers from a world-wide clinical dataset on Tourette syndrome. Eur Child Adolesc Psychiatry. 2007;16(Suppl 1):15-23. PMID: 17665279.

0     

Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. Mov Disord. 2007;22(2):179-86. PMID: 17094088.

710

Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-7. PMID: 17115387.

42

Hauser RA, Salin L, Juhel N, Konyago VL, NS 2330 Monotherapy PD Study Group. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord. 2007;22(3):359-65. PMID: 17149725.

91

Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007;69(15):1542-50. PMID: 17699801.

67

Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007;22(1):55-61. PMID: 17115391.

11

Jankovic J, Deng H. Candidate locus for chorea and tic disorders at 15q? Pediatr Neurol. 2007;37(1):70-3. PMID: 17628228.

131

Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007;21(8):677-92. PMID: 17630819.

76

Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007;13(7):411-6. PMID: 17442609.

114

Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: Double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64(5):676-82. PMID: 17502466.

0     

Johnson SA, Stout JC, Solomon AC, Langbehn DR, Aylward EH, Cruce CB, et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain. 2007;130(Pt 7):1732-44. PMID: 17584778.

53

Kenney C, Diamond A, Mejia N, Davidson A, Hunter C, Jankovic J. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007;263(1-2):94-9. PMID: 17604055.

42

Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007;22(1):10-3. PMID: 17078062.

122

Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193-7. PMID: 17133512.

10

Kenney C, Jankovic J. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Expert Opin Pharmacother. 2007;8(9):1329-35. PMID: 17563266.

67

Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2007;22(1):127-30. PMID: 17115386.

148

Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, et al. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007;106(4):621-5. PMID: 17432713.

35

Kenney CJ, Hunter CB, Mejia NI, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. J Pediatr Neurol. 2007;5(1):9-13.

27

Langbehn DR, Paulsen JS, Huntington Study Group. Predictors of diagnosis in Huntington disease. Neurology. 2007;68(20):1710-7. PMID: 17502553.

46

LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007;30(5):256-65. PMID: 17909303.

0     

LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262-7. PMID: 17438216.

53

May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007;22(16):2371-7. PMID: 17914727.

0     

Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, et al. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology. 2007;69(18):1737-44. PMID: 17804834.

7

Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, et al. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. Mov Disord. 2007;22(2):254-7. PMID: 17149721.

171

NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20-8. PMID: 17200487.

19

Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, et al. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007;22(4):546-9. PMID: 17230458.

0     

Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007;69(15):1480-90. PMID: 17881719.

194

Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342-7. PMID: 17581943.

65

Roessner V, Becker A, Banaschewski T, Freeman RD, Rothenberger A, Tourette Syndrome International Database Consortium. Developmental psychopathology of children and adolescents with Tourette syndrome--impact of ADHD. Eur Child Adolesc Psychiatry. 2007;16 Suppl 1:24-35. PMID: 17665280.

149

Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2007;13(2):67-76. PMID: 16887374.

151

Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J. GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology. 2007;68(2):159-60. PMID: 17210901.

47

Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007;7(6):637-47. PMID: 17563247.

32

Stamey W, Jankovic J. The other Babinski sign in hemifacial spasm. Neurology. 2007;69(4):402-4. PMID: 17646635.

30

Tan EK, Lee J, Hunter C, Shinawi L, Fook-Chong S, Jankovic J. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007;252(2):113-20. PMID: 17174340.

201

Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68(4):272-6. PMID: 17202432.

24

Wijemanne S, Jankovic J. Hemiparkinsonism-hemiatrophy syndrome. Neurology. 2007;69(16):1585-94. PMID: 17938368.

17

York MK, Lai EC, Jankovic J, Macias A, Atassi F, Levin HS, et al. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: A retrospective analysis. Acta Neurochir (Wien). 2007;149(9):857-66; discussion 866. PMID: 17624489.

109

Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Faseb J. 2007;21(14):3835-44. PMID: 17690154.

311

Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9(3):293-348. PMID: 16914840.

144

Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006;21(11):1856-63. PMID: 16941460.

19

Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006;21(9):1500-2. PMID: 16758485.

145

Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006;494(3):495-514. PMID: 16320253.

8

Clarke A, Jankovic J. Selegiline orally disintegrating tablet in the treatment of Parkinson's disease. Therapy. 2006;3(3):349-56. DOI: 10.2217/14750708.3.3.349.

41

Collins A, Jankovic J. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006;67(6):1083-5. PMID: 17000985.

23

Deng H, Le W, Davidson AL, Xie W, Jankovic J. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006;407(2):97-100. PMID: 16939701.

43

Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006;251(1-2):102-6. PMID: 17097110.

34

Deng H, Le WD, Hunter CB, Ondo WG, Guo Y, Xie WJ, et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006;63(2):273-7. PMID: 16476817.

59

Deng H, Le WD, Xie WJ, Jankovic J. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand. 2006;114(6):400-2. PMID: 17083340.

12

Deng H, Xie W, Guo Y, Le W, Jankovic J. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006;21(5):728-9. PMID: 16552756.

43

Deng H, Xie WJ, Le WD, Huang MS, Jankovic J. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006;401(1-2):16-9. PMID: 16530959.

14

Diamond A, Jankovic J. Botulinum toxin in dermatology - beyond wrinkles and sweat. J Cosmet Dermatol. 2006;5(2):169. PMID: 17173593.

34

Diamond A, Jankovic J. Treatment of advanced Parkinson's disease. Expert Rev Neurother. 2006;6(8):1181-97. PMID: 16893346.

19

Diamond A, Kenney C, Jankovic J. Effect of vagal nerve stimulation in a case of Tourette's syndrome and complex partial epilepsy. Mov Disord. 2006;21(8):1273-5. PMID: 16703589.

60

Diamond A, Shahed J, Azher S, Dat-Vuong K, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006;21(5):692-5. PMID: 16342255.

0     

Elble RJ, Pullman SL, Matsumoto JY, Raethjen J, Deuschl G, Tintner R, et al. Tremor amplitude is logarithmically related to 4- and 5-point tremor rating scales. Brain. 2006;129(Pt 10):2660-6. PMID: 16891320.

37

Elble RJ, Tremor Research Group. Report from a U.S. conference on essential tremor. Mov Disord. 2006;21(12):2052-61. PMID: 17078051.

23

Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Golbe LI, Verhagen L. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord. 2006;21(3):306-9. PMID: 16211613.

0     

Hoyos-Orrego A, Massaro-Ceballos M, Ospina-Ospina M, Gomez-Builes C, Vanegas-Arroyave N, Tobon-Pereira J, et al. Serological markers and risk factors for hepatitis B and C viruses in patients infected with human immunodeficiency virus. Rev Inst Med Trop Sao Paulo. 2006;48(6):321-6. PMID: 17221128.

0     

Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol. 2006;63(7):991-6. PMID: 16831969.

0     

Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366-72. PMID: 16476934.

65

Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67(12):2233-5. PMID: 17190952.

21

Jankovic J, Kwak C, Frankoff R. Tourette's syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006;18(1):86-95. PMID: 16525075.

18

Jankovic J, Mejia NI. Tics associated with other disorders. Adv Neurol. 2006;99:61-8. PMID: 16536352.

53

Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: Long-term outcome. CNS Spectr. 2006;11(7):501-8. PMID: 16816790.

37

Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006;73(4):682-9. PMID: 16878274.

55

Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006;9(2-3):145-8. PMID: 16785112.

0     

Jankovic J. Negotiating movement disorders. CNS Spectr. 2006;11(7):500.

207

Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5(10):864-72. PMID: 16987733.

147

Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006;103(28):10753-8. PMID: 16809426.

39

Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29(5):259-64. PMID: 16960470.

102

Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6(1):7-17. PMID: 16466307.

169

Mink JW, Walkup J, Frey KA, Como P, Cath D, Delong MR, et al. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2006;21(11):1831-8. PMID: 16991144.

108

Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006;66(5):672-7. PMID: 16436648.

19

Ondo WG, Silay Y, Almaguer M, Jankovic J. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006;21(8):1252-4. PMID: 16673406.

231

Pahwa R, Lyons KE, Wilkinson SB, Simpson RK, Jr, Ondo WG, et al. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006;104(4):506-12. PMID: 16619653.

23

Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, et al. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease. Mov Disord. 2006;21(12):2257-60. PMID: 17078063.

0     

Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, et al. Mutations in DJ-1 are rare in familial Parkinson disease. Neurosci Lett. 2006;408(3):209-13. PMID: 16997464.

107

Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: From disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3(3):138-48. PMID: 16511548.

0     

Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, et al. Preparing for preventive clinical trials: The Predict-HD study. Arch Neurol. 2006;63(6):883-90. PMID: 16769871.

182

Scahill L, Erenberg G, Berlin CM, Jr, Budman C, Coffey BJ, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3(2):192-206. PMID: 16554257.

97

Shatunov A, Sambuughin N, Jankovic J, Elble R, Lee HS, Singleton AB, et al. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006;129(Pt 9):2318-31. PMID: 16702189.

53

Tan EK, Jankovic J. Genetic testing in Parkinson disease: Promises and pitfalls. Arch Neurol. 2006;63(9):1232-7. PMID: 16966499.

67

Thomas M, Vuong KD, Jankovic J. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006;12(6):382-7. PMID: 16737838.

51

Wu LJ, Jankovic J. Runner's dystonia. J Neurol Sci. 2006;251(1-2):73-6. PMID: 17097111.

85

Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol. 2005;4(7):423-31. PMID: 15963445.

239

Azher SN, Jankovic J. Camptocormia: Pathogenesis, classification, and response to therapy. Neurology. 2005;65(3):355-9. PMID: 16087897.

157

Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423-9. PMID: 16275831.

123

Deng H, Jankovic J, Guo Y, Xie W, Le W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun. 2005;337(4):1133-8. PMID: 16226715.

74

Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005;57(6):933-4. PMID: 15929036.

36

Deng H, Le WD, Guo Y, Huang MS, Xie WJ, Jankovic J. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 2005;65(4):651-2. PMID: 16116142.

14

Deng H, Le WD, Xie WJ, Pan TH, Zhang X, Jankovic J. Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. Neurosci Lett. 2005;382(3):297-9. PMID: 15925106.

14

Deng H, Le WD, Zhang X, Pan TH, Jankovic J. G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurol Scand. 2005;111(6):351-2. PMID: 15876334.

98

Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005;76(9):1188-93. PMID: 16107348.

0     

Henao JA, Vanegas N, Cano OD, Hiromi JC, Rugeles MT. [The human immunodeficiency virus type 1 and the developing central nervous system]. Biomedica. 2005;25(1):136-47. PMID: 15962910.

55

Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;64(3):417-21. PMID: 15699368.

52

Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord. 2005;20(3):293-7. PMID: 15584032.

24

Imam SZ, Jankovic J, Ali SF, Skinner JT, Xie W, Conneely OM, et al. Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice. Faseb J. 2005;19(11):1441-50. PMID: 16126911.

232

Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005;77(1-2):128-38. PMID: 16243425.

24

Jankovic J, Noebels JL. Genetic mouse models of essential tremor: Are they essential? J Clin Invest. 2005;115(3):584-6. PMID: 15765140.

11

Jankovic J. Dystonia and other deformities in Parkinson's disease. J Neurol Sci. 2005;239(1):1-3. PMID: 16199057.

340

Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005;20 Suppl 11:S11-6. PMID: 15822109.

47

Jankovic J. Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol. 2005;62(3):351-2. PMID: 15767498.

117

Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology. 2005;64(12):2021-8. PMID: 15985567.

109

Jiang C, Wan X, He Y, Pan T, Jankovic J, Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol. 2005;191(1):154-62. PMID: 15589522.

0     

Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D, SELECT-TC Study Group. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm (Vienna). 2005;112(2):221-30. PMID: 15503197.

24

Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005;20(1):86-9. PMID: 15390048.

41

Mejia NI, Jankovic J. Secondary tics and tourettism. Rev Bras Psiquiatr. 2005;27(1):11-7. PMID: 15867978.

137

Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20(5):592-7. PMID: 15645481.

54

Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005;20 Suppl 11:S3-10. PMID: 15822111.

189

Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: Double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636-9. PMID: 16291885.

70

Pan T, Li X, Xie W, Jankovic J, Le W. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 2005;579(30):6716-20. PMID: 16313906.

38

Pan T, Xie W, Jankovic J, Le W. Biological effects of pramipexole on dopaminergic neuron-associated genes: Relevance to neuroprotection. Neurosci Lett. 2005;377(2):106-9. PMID: 15740846.

0     

Paulsen JS, Hoth KF, Nehl C, Stierman L, Huntington Study Group. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry. 2005;162(4):725-31. PMID: 15800145.

8

Ross S, Jankovic J. Palatal myoclonus: an unusual presentation. Mov Disord. 2005;20(9):1200-3. PMID: 15929094.

25

Shatunov A, Jankovic J, Elble R, Sambuughin N, Singleton A, Hallett M, et al. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;65(12):1995; author reply 1995. PMID: 16380635.

33

Silay YS, Jankovic J. Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs. 2005;10(2):365-80. PMID: 15934872.

61

Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: A double-blind, randomized trial. Neurology. 2005;65(5):765-7. PMID: 16157918.

42

Tintner R, Manian P, Gauthier P, Jankovic J. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005;62(8):1290-5. PMID: 16087771.

163

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20(7):783-91. PMID: 15736159.

20

Wan XH, Vuong KD, Jankovic J. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005;20(1):44-7. PMID: 15844312.

27

Brodsky H, Dat Vuong K, Thomas M, Jankovic J. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004;63(6):1096-8. PMID: 15452308.

297

Bruno MK, Hallett M, Gwinn-Hardy K, Sorensen B, Considine E, Tucker S, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: New diagnostic criteria. Neurology. 2004;63(12):2280-7. PMID: 15623687.

17

de Carvalho Aguiar P, Fazzari M, Jankovic J, Ozelius LJ. Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov Disord. 2004;19(10):1237-8. PMID: 15368614.

48

Deng H, Le W, Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. Jama. 2004;292(14):1685-6. PMID: 15479932.

21

Higgins JJ, Lombardi RQ, Tan EK, Jankovic J, Pucilowska J, Rooney JP. Haplotype analysis at the ETM2 locus in a Singaporean sample with familial essential tremor. Clin Genet. 2004;66(4):353-7. PMID: 15355439.

0     

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-53. PMID: 15262734.

28

Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27(5):234-44. PMID: 15602105.

37

Jankovic J, Madisetty J, Vuong KD. Essential tremor among children. Pediatrics. 2004;114(5):1203-5. PMID: 15520096.

265

Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75(7):951-7. PMID: 15201348.

38

Jankovic J. Dystonia: Medical therapy and botulinum toxin. Adv Neurol. 2004;94:275-86. PMID: 14509685.

2

Jankovic J. Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology. 2004;63(8):1541-2; author reply 1541-2. PMID: 15505193.

90

Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004;19 Suppl 8:S109-15. PMID: 15027062.

13

Jiang C, Wan X, Jankovic J, Christian ST, Pristupa ZB, Niznik HB, et al. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004;27(2):63-73. PMID: 15252266.

8

Lassinger BK, Kwak C, Walford RL, Jankovic J. Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: A possible complication of chronic hypoxia and carbon monoxide toxicity? Mov Disord. 2004;19(4):465-9. PMID: 15077246.

109

Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004;62(11):2005-9. PMID: 15184605.

188

Naumann M, Jankovic J. Safety of botulinum toxin type A: A systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7):981-90. PMID: 15265242.

32

Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, et al. Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Mov Disord. 2004;19(6):649-55. PMID: 15197702.

0     

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61(10):1563-8. PMID: 15477510.

23

Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004;27(6):274-7. PMID: 15613931.

4

Pan T, Le W, Jankovic J. Slowing Parkinson's disease progression: Recent dopamine agonist trials. Neurology. 2004;62(2):343; author reply 343-4. PMID: 14750218.

0     

Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, et al. Genes influencing Parkinson disease onset: Replication of PARK3 and identification of novel loci. Neurology. 2004;62(9):1616-8. PMID: 15136695.

1216

Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-508. PMID: 15590952.

7

Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004;94:29-36. PMID: 14509651.

202

Suteerawattananon M, Morris GS, Etnyre BR, Jankovic J, Protas EJ. Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci. 2004;219(1-2):63-9. PMID: 15050439.

86

Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004;19(6):692-5. PMID: 15197710.

115

Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004;19(1):36-42. PMID: 14743358.

77

Thomas M, Jankovic J, Suteerawattananon M, Wankadia S, Caroline KS, Vuong KD, et al. Clinical Gait and Balance Scale (GABS): Validation and utilization. J Neurol Sci. 2004;217(1):89-99. PMID: 14675615.

94

Thomas M, Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol. 2004;17(4):437-42. PMID: 15247539.

75

Thomas M, Jankovic J. Psychogenic movement disorders: Diagnosis and management. CNS Drugs. 2004;18(7):437-52. PMID: 15139799.

175

Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology. 2003;60(5):796-801. PMID: 12629236.

0     

Frampton JE, Easthope SE. Botulinum toxin A (Botox Cosmetic): A review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003;4(10):709-25. PMID: 14507232.

15

Handforth A, Ondo WG, Tatter S, Mathern GW, Simpson RK, Jr, et al. Vagus nerve stimulation for essential tremor: a pilot efficacy and safety trial. Neurology. 2003;61(10):1401-5. PMID: 14638963.

115

He Y, Imam SZ, Dong Z, Jankovic J, Ali SF, Appel SH, et al. Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem. 2003;86(6):1338-45. PMID: 12950443.

29

Higgins JJ, Jankovic J, Lombardi RQ, Pucilowska J, Tan EK, Ashizawa T, et al. Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics. 2003;4(4):185-9. PMID: 12761658.

20

Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord. 2003;18(10):1190-2. PMID: 14534926.

24

Hou JG, Jankovic J. Movement disorders in Friedreich's ataxia. J Neurol Sci. 2003;206(1):59-64. PMID: 12480086.

0     

Hoyos-Orrego A, Vanegas N. Western blot false negative test in a patient with AIDS. Infectio. 2003;7(3):173-6.

243

Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186-8. PMID: 12682332.

21

Kuniyoshi SM, Jankovic J. MDMA and Parkinsonism. N Engl J Med. 2003;349(1):96-7. PMID: 12840102.

160

Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003;18(12):1530-3. PMID: 14673893.

47

Kwak C, Vuong KD, Jankovic J. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003;60(11):1595-8. PMID: 14623732.

362

Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003;33(1):85-9. PMID: 12496759.

195

Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003;12(24):3259-67. PMID: 14570706.

42

Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol. 2003;10(1):68-79. PMID: 12785750.

75

Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, et al. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003;26(7):461-81. PMID: 12735785.

0     

Mahant N, McCusker EA, Byth K, Graham S, Huntington Study Group. Huntington's disease: Clinical correlates of disability and progression. Neurology. 2003;61(8):1085-92. PMID: 14581669.

623

Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60(1):69-73. PMID: 12525720.

48

Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, et al. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003;60(7):975-80. PMID: 12873854.

62

Ondo WG, Sutton L, Dat Vuong K, Lai D, Jankovic J. Hearing impairment in essential tremor. Neurology. 2003;61(8):1093-7. PMID: 14581670.

68

Pan T, Fei J, Zhou X, Jankovic J, Le W. Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. Life Sci. 2003;72(9):1073-83. PMID: 12495785.

105

Pan T, Jankovic J, Le W. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging. 2003;20(10):711-21. PMID: 12875608.

114

Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 2003;12(20):2599-608. PMID: 12925570.

122

Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet. 2003;72(4):1053-7. PMID: 12638082.

0     

Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003;60(12):1721-8. PMID: 14676046.

0     

Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T, et al. Reliability of reported age at onset for Parkinson's disease. Mov Disord. 2003;18(3):275-9. PMID: 12621630.

3

Rosa AL, Jankovic J, Ashizawa T. Screening for mutations in the MECP2 (Rett syndrome) gene in Gilles de la Tourette syndrome. Arch Neurol. 2003;60(4):502-3. PMID: 12707062.

12

Sabbahi M, Etnyre B, Al-Jawayed I, Jankovic J. Soleus H-reflex measures in patients with focal and generalized dystonia. Clin Neurophysiol. 2003;114(2):288-94. PMID: 12559236.

68

Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery. 2003;52(6):1358-70; discussion 1370-3. PMID: 12762881.

16

Savant CS, Singhal BS, Jankovic J, Khan M, Virani A. Substantia nigra lesions in viral encephalitis. Mov Disord. 2003;18(2):213-6. PMID: 12539218.

28

Simon DK, Friedman J, Breakefield XO, Jankovic J, Brin MF, Provias J, et al. A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics. 2003;4(4):199-205. PMID: 12756609.

19

Simpkins N, Jankovic J. Neuroprotection in Parkinson disease. Arch Intern Med. 2003;163(14):1650-4. PMID: 12885679.

47

Thomas M, Le WD, Jankovic J. Minocycline and other tetracycline derivatives: A neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol. 2003;26(1):18-23. PMID: 12567160.

24

Tintner R, Jankovic J. Dopamine agonists in Parkinson's disease. Expert Opin Investig Drugs. 2003;12(11):1803-20. PMID: 14585056.

15

van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, Watts RL, et al. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003;60(7):1189-91. PMID: 12682333.

439

van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003;72(4):804-11. PMID: 12618962.

49

Walker RH, Jankovic J, O'Hearn E, Margolis RL. Phenotypic features of Huntington's disease-like 2. Mov Disord. 2003;18(12):1527-30. PMID: 14673892.

81

Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, et al. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60(6):998-1001. PMID: 12654967.

39

Blakeley J, Jankovic J. Secondary causes of paroxysmal dyskinesia. Adv Neurol. 2002;89:401-20. PMID: 11968464.

100

Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias. Mov Disord. 2002;17(4):726-34. PMID: 12210862.

39

Dolimbek BZ, Jankovic J, Atassi MZ. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002;31(3-4):247-62. PMID: 12472183.

0     

Hoyos-Orrego A, Vanegas N, Paez E. Epidemiology of hepatitis C virus in Colombia. Acta Med Colomb. 2002;27(4):209-20.

43

Jankovic J, Demirkiran M. Classification of paroxysmal dyskinesias and ataxias. Adv Neurol. 2002;89:387-400. PMID: 11968463.

64

Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002;8(4):271-6. PMID: 12039422.

122

Jankovic J. Essential tremor: A heterogenous disorder. Mov Disord. 2002;17(4):638-44. PMID: 12210851.

102

Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58(4 Suppl 1):S19-32. PMID: 11909982.

91

Krauss JK, Jankovic J. Head injury and posttraumatic movement disorders. Neurosurgery. 2002;50(5):927-39; discussion 939-40. PMID: 11950395.

47

Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord. 2002;17(4):821-5. PMID: 12210884.

255

Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002;70(4):985-93. PMID: 11875758.

48

Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, et al. Linkage stratification and mutation analysis at the Parkin locus identifies mutation positive Parkinson's disease families. J Med Genet. 2002;39(7):489-92. PMID: 12114481.

141

Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17(5):1031-5. PMID: 12360554.

65

Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002;25(6):300-2. PMID: 12469001.

305

Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59(3):421-4. PMID: 11890847.

89

Opal P, Tintner R, Jankovic J, Leung J, Breakefield XO, Friedman J, et al. Intrafamilial phenotypic variability of the DYT1 dystonia: From asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord. 2002;17(2):339-45. PMID: 11921121.

144

Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet. 2002;71(1):124-35. PMID: 12058349.

0     

Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Jama. 2002;287(13):1653-61. PMID: 11926889.

185

Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002;58(3):341-6. PMID: 11839829.

10

Sabbahi M, Etnyre B, Al-Jawayed I, Jankovic J. H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002;19(3):245-51. PMID: 12226570.

11

Sabbahi M, Etnyre B, Al-Jawayed IA, Hasson S, Jankovic J. Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002;19(1):67-72. PMID: 11896355.

41

Sethi KD, Jankovic J. Dystonia in spinocerebellar ataxia type 6. Mov Disord. 2002;17(1):150-3. PMID: 11835453.

0     

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51(5):604-12. PMID: 12112107.

40

Tintner R, Jankovic J. Treatment options for Parkinson's disease. Curr Opin Neurol. 2002;15(4):467-76. PMID: 12151845.

92

Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T, et al. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002;58(6):881-4. PMID: 11914402.

0     

Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345(13):956-63. PMID: 11575287.

371

Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, et al. Freezing of gait in PD: Prospective assessment in the DATATOP cohort. Neurology. 2001;56(12):1712-21. PMID: 11425939.

35

Hanna PA, Ratkos L, Ondo WG, Jankovic J. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm. 2001;108(1):63-70. PMID: 11261747.

28

Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov Disord. 2001;16(6):1201-2. PMID: 11748766.

5

Jankovic J, Demirkiran M. Paroxysmal dyskinesias: An update. Ann Med Sci. 2001;10(3):92-103.

307

Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58(10):1611-5. PMID: 11594919.

3

Jankovic J, Lai EC, Ondo WG, Roberts-Warrior D, Olson SL, Krauss JK, et al. Effects of pallidotomy on gait and balance. Adv Neurol. 2001;87:271-81. PMID: 11347232.

40

Jankovic J, Nutt JG, Sudarsky L. Classification, diagnosis, and etiology of gait disorders. Adv Neurol. 2001;87:119-33. PMID: 11347215.

89

Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001;8(2):109-21. PMID: 11489676.

145

Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord. 2001;16(1):7-12. PMID: 11215595.

40

Jankovic J. Differential diagnosis and etiology of tics. Adv Neurol. 2001;85:15-29. PMID: 11530424.

45

Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve. 2001;24(11):1568-70. PMID: 11745964.

26

Jankovic J. Parkinson's disease therapy: Treatment of early and late disease. Chin Med J (Engl). 2001;114(3):227-34. PMID: 11780303.

15

Jankovic J. Parkinson's disease. A half century of progress. Neurology. 2001;57(10 Suppl 3):S1-3. PMID: 11771154.

8

Jankovic J. Surgery for Parkinson disease and other movement disorders: Benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol. 2001;58(12):1970-2. PMID: 11735770.

345

Jankovic J. Tourette's syndrome. N Engl J Med. 2001;345(16):1184-92. PMID: 11642235.

60

Krauss JK, Simpson RK, Jr, Ondo WG, Pohle T, Burgunder JM, et al. Concepts and methods in chronic thalamic stimulation for treatment of tremor: Technique and application. Neurosurgery. 2001;48(3):535-41; discussion 541-3. PMID: 11270543.

83

Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001;18(6):389-96. PMID: 11419913.

31

Leckman JF, Cohen DJ, Goetz CG, Jankovic J. Tourette syndrome: Pieces of the puzzle. Adv Neurol. 2001;85:369-90. PMID: 11530445.

148

Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics. 2001;3(3):133-43. PMID: 11523564.

160

Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. Jama. 2001;286(18):2245-50. PMID: 11710889.

87

Ondo W, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001;58(2):218-22. PMID: 11176959.

18

Ondo W, Dat Vuong K, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001;16(6):1137-42. PMID: 11748749.

292

Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001;57(8):1392-6. PMID: 11673578.

39

Sambuughin N, Nelson TE, Jankovic J, Xin C, Meissner G, Mullakandov M, et al. Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul Disord. 2001;11(6-7):530-7. PMID: 11525881.

253

Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, et al. Complete genomic screen in Parkinson disease: Evidence for multiple genes. Jama. 2001;286(18):2239-44. PMID: 11710888.

29

Shahed J, Jankovic J. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001;16(1):114-8. PMID: 11215569.

10

Swoboda KJ, Soong BW, McKenna C, Brunt ER, Litt M, Bale JF, et al. Paroxysmal kinesigenic dyskinesia and infantile convulsions. Clinical and linkage studies. 2000. Neurology. 2001;57(11 Suppl 4):S42-8. PMID: 11775608.

29

Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001;24(5):247-53. PMID: 11586109.

45

Tan EK, Jankovic J. Psychogenic hemifacial spasm. J Neuropsychiatry Clin Neurosci. 2001;13(3):380-4. PMID: 11514645.

10

Tan EK, Nagamitsu S, Matsuura T, Khajavi M, Jankovic J, Ondo W, et al. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001;305(1):70-2. PMID: 11356310.

15

Tintner R, Jankovic J. Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother. 2001;2(12):1985-94. PMID: 11825330.

15

Tintner R, Jankovic J. Focal dystonia: The role of botulinum toxin. Curr Neurol Neurosci Rep. 2001;1(4):337-45. PMID: 11898539.

57

Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord. 2001;16(2):252-7. PMID: 11295777.

25

Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord. 2001;7(2):115-20. PMID: 11248592.

15

Xu P, Liang X, Jankovic J, Le W. Identification of a high frequency of mutation at exon 8 of the ATP7B gene in a Chinese population with Wilson disease by fluorescent PCR. Arch Neurol. 2001;58(11):1879-82. PMID: 11708998.

74

Yoshor D, Hamilton WJ, Ondo W, Jankovic J, Grossman RG. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001;48(4):818-24; discussion 824-6. PMID: 11322442.

162

Bain P, Brin M, Deuschl G, Elble R, Jankovic J, Findley L, et al. Criteria for the diagnosis of essential tremor. Neurology. 2000;54(11 Suppl 4):S7. PMID: 10854345.

62

Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology. 2000;55(12 Suppl 5):S15-21. PMID: 11188979.

23

Hallett M, Litvan I, Task Force on Surgery for Parkinson's Disease of the American Academy of Neurology Therapeutic and Technology Assessment Committee. Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease. Mov Disord. 2000;15(3):436-8. PMID: 10830406.

44

Higgins JJ, Golbe LI, De Biase A, Jankovic J, Factor SA, Adler RL. An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy. Neurology. 2000;55(9):1364-7. PMID: 11087782.

163

Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000;57(3):369-72. PMID: 10714663.

1

Jankovic J. Atypical and typical cranial dystonia following dental procedures. Mov Disord. 2000;15(2):366. PMID: 10752604.

52

Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology. 2000;55(12 Suppl 6):S2-6. PMID: 11188970.